CA2156410A1

CA2156410A1 - Pyrrolo-pyridine derivatives

Info

Publication number: CA2156410A1
Application number: CA002156410A
Authority: CA
Inventors: Raymond Baker; Neil Roy Curtis; Janusz Jozef Kulagowski; Paul David Leeson; Adrian Leonard Smith; Mark Peter Ridgill
Original assignee: Individual
Current assignee: Organon Pharma UK Ltd
Priority date: 1993-03-01
Filing date: 1994-02-25
Publication date: 1994-09-15
Also published as: EP0687267A1; EP0687267B1; AU6042294A; WO1994020459A2; AU679040B2; WO1994020459A3; JPH09500357A

Abstract

Compounds of formula (1), wherein Q is (Qa), (Qb), (Oc), are ligands for dopamine receptor subtypes within the body and are therefore useful in the treatment and/or prevention of disorders of the dopamine system, in prevention of disorders of the dopamine system, in particular schizophrenia.

Description

W094/20459 2 1 ~ 6 4 1 ~ PCT/GB94100384 PYR~OLO-PYRIDINE DERIVATIVES

This invention relates to a particular class of heteroaromatic compounds. More particularly, the invention is concerned with substituted pyrrolot2,3-b]-pyridine derivatives which are ligands for dopamine receptor subtypes within the body and are therefore of use in the treatment and/or prevention of disorders of the dopamine system, including schizophrenia, depression, nausea, Parkinson's disease, tardive dyskinesias and extrapyramidal side-effects associated with treatment by conventional neuroleptic agents, neuroleptic malignant syndrome, and disorders of hypothalamic-pituitary function such as hyperprolactinaemia and amenorrhoea.
Upper gastrointestinal tract motility is believed to be under the control of the dopamine system.
The compounds according to the present invention may thus be of use in the prevention and/or treatment of gastrointestinal disorders, and the facilitation of gastric emptying.
Dependence-inducing agents such as ***e and amphetamine have been shown to interact with the dopamine system. Compounds capable of counteracting this effect, including the compounds in accordance with the present invention, may accordingly be of value in the prevention or reduction of dependence on a dependence-inducing agent.
Dopamine is known to be a peripheral vasodilator; for example, it has been shown to exert a dilatory effect on the renal vascular bed. This implies that the compounds of the present invention may be beneficial in controlling vascular blood flow.
The localisation of dopamine receptor mRNA in rat heart and large vessels has been noted. This suggests a role for dopamine receptor ligands in W094t20459 PCT/GB94/00384 r3 6 ~ ~

controlling cardiovascular function, either by affecting cardiac and smooth muscle contractility or by modulating the secretion of vasoactive substances. The compounds according to the present invention may therefore be of assistance in the prevention and/or treatment of such conditions as hypertension and congestive heart failure.
Molecular biological techniques have revealed the existence of several subtypes of the dopamine receptor. The dopamine Dl receptor subtype has been shown to occur in at least two discrete forms. Two forms of the D2 receptor subtype, and at least one form of the D3 receptor subtype, have also been discovered. More recently, the D4 (Van Tol et al., Nature (London), 1991, 350, 610) and D5 (Sunahara et al., Nature (London), 1991, 350, 614) receptor subtypes have been described.
The disclosure of GB-A-2044254 generically encompasses inter alia a class of 3-[piperidin-1-ylalkyl]-lH-pyrrolo[2,3-b]pyridine derivatives substituted on the piperidine ring by an isoindoledione or like moiety. These compounds are alleged therein to be useful as antidepressants. There is, however, no specific disclosure in GB-A-2044254 of a substituted pyrrolo[2,3-b]pyridine derivative, nor indeed any suggestion that such compounds would be of benefit in the treatment and/or prevention of disorders of the dopamine system.
The compounds in accordance with the present invention, being ligands for dopamine receptor subtypes within the body, are accordingly of use in the treatment and/or prevention of disorders of the dopamine system.
The present invention accordingly provides a compound of formula I, or a salt or prodrug thereof:

W094/20459 21~ 6 ~ i O PCT/GB94/00384 R4 l3 CH2-Q

R 5/\ N N

( I ) wherein R represents hydrogen or Cl_6 alkyl;
Q represents a moiety of formula Qa, Qb or Qc:

R 1 R ~ R6 N~R2 --N~=CHR2 N~

(Qa) (Qb) (Qc) in which the broken line represents an optional chemical bond;
Rl represents hydrogen, or an optionally substituted C1_6 alkyl, Cl_6 alkoxy, C2_6 alkenyl, C2_6 alkynyl, aryl, aryl(Cl_6)alkyl, aryl(Cl_6)alkoxy, aryl(C2_6)alkenyl, aryl(C2-6)alkynyl, C3_7 heterocycloalkyl(Cl_6)alkyl, heteroaryl, heteroaryl(Cl-6)alkyl, heteroaryl(C2-6)alkenyl or heteroaryl(C2_6)alkynyl group;
R2 represents an optionally substituted Cl_6 alkyl, Cl_6 alkoxy, C2_6 alkenyl, C2_6 alkynyl, aryl, aryl(Cl_6)alkyl, aryloxy(Cl_6)alkyl, aryl(Cl_6)alkoxy, aryl(C2_6)alkenyl, aryl(C2_6)alkynyl, C3_7 heterocycloalkyl(C1_6)alkyl, heteroaryl, 2ls6~

heteroaryl(C1_6)alkyl, heteroaryl(C2_6)alkenyl or heteroaryl(C2_6)alkynyl group;
R3, R4 and R5 independently represent hydrogen, hydrocarbon, a heterocyclic group, halogen, cyano, trifluoromethyl, nitro, -ORa, -SRa, -SORa, -SO2Ra, -SO2NRaRb, -NRaRb, -NRaCORb, -NRaCO2Rb, -CORa, -CO2Ra or -CONRaRb;
Z represents -CH2- or -CH2CH2-;
R6 represents hydrogen or halogen, or an optionally substituted Cl_6 alkyl, Cl_6 alkoxy, aryl, aryloxy, aryl(Cl_6)alkyl, aryl(Cl_6)alkoxy or heteroaryl group; and Ra and Rb independently represent hydrogen, hydrocarbon or a heterocyclic group.
For use in medicine, the salts of the compounds of formula I will be pharmaceutically acceptable salts.
Other salts may, however, be useful in the preparation of the compounds according to the invention or of their pharmaceutically acceptable salts. Suitable pharmaceutically acceptable salts of the compounds of this invention include acid addition salts which may, for example, be formed by mixing a solution of the compound according to the invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulphuric acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, oxalic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid.
Furthermore, where the compounds of the invention carry an acidic moiety, suitable pharmaceutically acceptable salts thereof may include alkali metal salts, e.g. sodium or potassium salts; alkaline earth metal salts, e.g.
calcium or magnesium salts; and salts formed with suitable organic ligands, e.g. quaternary ammonium salts.
The term "hydrocarbon" as used herein includes straight-chained, branched and cyclic groups containing up to 18 carbon atoms, suitably up to 15 carbon atoms, W094/20459 2 1 5 6 4 l O PCT/GB94/00384 and conveniently up to 12 carbon atoms. Suitable hydrocarbon groups include Cl_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_7 cycloalkyl, C3_7 cycloalkyl(Cl_6)alkyl, aryl, aryl(Cl_6)alkyl, aryl(C2_6)alkenyl and aryl(C2_6)alkynyl.
The expression "a heterocyclic group" as used herein includes cyclic groups containing up to 18 carbon atoms and at least one heteroatom preferably selected from oxygen, nitrogen and sulphur. The heterocyclic group suitably contains up to 15 carbon atoms and conveniently up to 12 carbon atoms, and is preferably linked through carbon. Examples of suitable heterocyclic groups include C3_7 heterocycloalkyl, C3_7 heterocycloalkyl(C1_6)alkyl, heteroaryl, heteroaryl(cl_6)alkyl, heteroaryl(C2_6)alkenyl and heteroaryl(C2_6)alkynyl groups.
Suitable alkyl groups within the scope of the term "hydrocarbon" and within the definition of the substituents R, Rl, R2 and R6 include straight-chained and branched alkyl groups containing from 1 to 6 carbon atoms. Typical examples include methyl and ethyl groups, and straight-chained or branched propyl and butyl groups.
Particular alkyl groups are methyl, ethyl, n-propyl, isopropyl and t-butyl.
Suitable alkenyl groups within the scope of the term "hydrocarbon" and within the definition of the substituents Rl and R2 include straight-chained and branched alkenyl groups containing from 2 to 6 carbon atoms. Typical examples include vinyl and allyl groups.
Suitable alkynyl groups within the scope of the term "hydrocarbon" and within the definition of the substituents R1 and R2 include straight-chained and branched alkynyl groups containing from 2 to 6 carbon atoms. Typical examples include ethynyl and propargyl groups.

W094/20459 ~ ~S 6 ~ ~ PCT/GB94/00384 Suitable cycloalkyl groups include groups containing from 3 to 7 carbon atoms. Particular cycloalkyl groups are cyclopropyl and cyclohexyl.
Particular aryl groups within the scope of the term "hydrocarbon" and within the definition of the substituents Rl, R2 and R6 include phenyl and naphthyl.
Particular aryl(Cl_6)alkyl groups within the scope of the term "hydrocarbon" and within the definition of the substituents Rl, R2 and R6 include benzyl, naphthylmethyl, phenethyl and phenylpropyl.
A particular aryl(C2_6)alkenyl group within the scope of the term "hydrocarbon" and within the definition of the substituents Rl and R2 is phenylethenyl.
A particular aryl(C2_6)alkynyl group within the scope of the term "hydrocarbon" and within the definition of the substituents Rl and R2 is phenylethynyl.
Suitable heterocycloalkyl groups include azetidinyl, pyrrolidyl, piperidyl, piperazinyl, morpholinyl and tetrahydrofuryl groups.
A particular C3_7 heterocycloalkyl(Cl_6)alkyl group within the scope of the expression "a heterocyclic group" and within the definition of the substituents and R2 is tetrahydrofurylethyl.
Suitable heteroaryl groups within the scope of the expression "a heterocyclic group" and within the definition of the substituents Rl, R2 and R6 include pyridyl, quinolyl, isoquinolyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyranyl, furyl, benzofuryl, dibenzofuryl, thienyl, benzthienyl, indolyl, indazolyl, imidazolyl, benzimidazolyl, oxadiazolyl and thiadiazolyl groups.
Particular heteroaryl(Cl_6)alkyl groups within the scope of the expression "a heterocyclic group" and within the definition of the substituents R1 and R2 include thienylmethyl, pyridylmethyl, pyrimidinylmethyl, pyrazinylmethyl and furylethyl.

W094/20459 21~ PCT/GB94/00384 Particular heteroaryl(C2_6)alkenyl groups within the scope of the term "hydrocarbon" and within the definition of the substituents Rl and R2 include furylethenyl and thienylethenyl.
- 5 The hydrocarbon and heterocyclic groups, as well as the substituents Rl, R2 and R6, may in turn be optionally substituted by one or more groups selected from Cl_6 alkyl, adamantyl, phenyl, aryl(C1_6)alkyl, halogen, Cl_6 haloalkyl, Cl_6 aminoalkyl, trifluoromethyl, hydroxy, Cl_6 alkoxy, aryloxy, keto, Cl_3 alkylenedioxy, nitro, cyano, carboxy, C2_6 alkoxycarbonyl, C2_6 alkoxycarbonyl(C1_6)alkyl, C2_6 alkylcarbonyloxy, arylcarbonyloxy, C2_6 alkylcarbonyl, arylcarbonyl, C1_6 alkylthio, Cl_6 alkylsulphinyl, Cl_6 alkylsulphonyl, arylsulphonyl, trifluoromethane-sulphonyloxy, -NRVRw, -NRVCORw, -NRVCO2Rw, -NRVso2R
-CH2NRVS02RW, -NHCONRVRw, -PO(ORV)(ORW), -CONRVRw, -SO2NRVRw and -CH2SO2NRVRw, in which Rv and Rw independently represent hydrogen, Cl_6 alkyl, aryl or aryl(Cl_6)alkyl.
The term "halogen" as used herein includes fluorine, chlorine, bromine and iodine, especially chlorine.
The present invention includes within its scope prodrugs of the compounds of formula I above. In general, such prodrugs will be functional derivatives of the compounds of formula I which are readily convertible in vivo into the required compound of formula I.
Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs", ed. H. Bundgaard, Elsevier, 1985.
Where the compounds according to the invention have at least one asymmetric centre, they may accordingly exist as enantiomers. Where the compounds according to the invention possess two or more asymmetric centres, 2 ~5 ~4~10 - 8 -they may additionally exist as diastereoisomers. It is to be understood that all such isomers and mixtures thereof are encompassed within the scope of the present invention.
Suitably, the substituent R represents hydrogen or methyl, especially hydrogen.
Suitably, the substituent Rl represents hydrogen.
Suitable values for the substituent R2 include Cl_6 alkyl, aryl, aryl(Cl_6)alkyl, aryloxy(Cl_6)alkyl, aryl(C2_6)alkenyl, aryl(C2_6)alkynyl, C3_7 heterocycloalkyl(Cl_6)alkyl, heteroaryl, heteroaryl(Cl_6)alkyl or heteroaryl(C2_6)alkenyl, any of which groups may be optionally substituted. Examples of optional substituents on the group R2 include Cl_6 alkyl, halogen, nitro, Cl_6 alkoxy, aryloxy and arylcarbonyloxy.
Particular values of R2 include methyl, benzoyloxy-methyl, ethyl, n-propyl, isopropyl, phenyl, chlorophenyl, ethylphenyl, methoxyphenyl, nitrophenyl, naphthyl, benzyl, chlorobenzyl, phenethyl, phenoxy-methyl, phenylethenyl, chloro-phenylethenyl, methoxy-phenylethenyl, phenylethynyl, tetrahydrofuryl-ethyl, indolyl, benzofuryl, benzthienyl, furylethyl, methyl-furylethyl, thienylethenyl and methyl-furylethenyl.
Suitable values for the substituents R3, R4 and R5 include hydrogen, halogen, cyano, nitro, trifluoromethyl, amino, Cl_6 alkylamino, di(Cl_6)alkylamino, Cl_6 alkyl, Cl_6 alkoxy, aryl(Cl_6)alkoxy and C2_6 alkylcarbonyl. Particular values include hydrogen, fluoro, chloro, methyl, methoxy and benzyloxy.
Particular values of R6 include hydrogen, methoxy, phenyl, chlorophenyl, phenoxy, benzyloxy, thienyl, chloro and bromo.

~094/2~iS9 21 S641 ~ PCT/GB94/00384 one sub-class of compounds according to the invention is represented by the compounds of formula IIA, and salts and prodrugs thereof:

~ y _ E-W
N
~ X

Rl3 N

( I IA) wherein E represents -(CH2)n~, -CH=CH- or -C-C-;
n is zero, 1, 2 or 3;
-X-Y- represents -CH2-CH- or -CH=C-;
W represents a group of formula (i), (ii), (iii), (iv), (v) or (vi):

Rl7 Rl7 R~7 (I) (Il) (Itl) R 1 7~ R 1 7 ~R

( I V) ( V ) ( V i ) in which V represents oxygen, sulphur or NH; and W094/20459 ~ ~ 6 ~ -~ PCT/GB94/00384 R13 and R17 independently represent hydrogen, halogen, cyano, nitro, trifluoromethyl, amino, C1_6 alkylamino, di(C1_6)alkylamino, C1_6 alkyl, C1_6 alkoxy~
aryl(Cl_6)alkoxy or C2_6 alkylcarbonyl.
Particular values of R13 include hydrogen, fluoro, chloro, methyl, ethyl, methoxy and benzyloxy.
Particular values of R17 include hydrogen, chloro, methyl, methoxy and nitro.
A particular subset of the compounds of formula IIA as defined above is represented by the compounds of formula IIB, and salts and prodrugs thereof:

/--\y_( CH2 ) n~R I 7 R ~ 3~--( I 1~) wherein n, X, Y, R13 and R17 are as defined with reference to formula IIA above.
Another sub-class of compounds according to the invention is represented by the compounds of formula IIC, and salts and prodrugs thereof:

~~y_U~
~N

N\H

(I IC) - wherein W094/20459 2 ~ S 6 ~ 1 o PCTIGB94/00384 U represents -CH=CH-, -C-C- or -CH2O-; and X, Y, R13 and R17 are as defined with reference to formula IIA above.
A particular subset of the compounds of formula IIC as defined above comprises those compounds wherein U
represents -CH=CH-, in particular in the (E) configuration.
A further sub-class of compounds according to the invention is represented by the compounds of formula lO IID, and salts and prodrugs thereof:

N ~ R16 N

( I ID) wherein R13 is as defined with reference to formula IIA
above; and R16 represents hydrogen, halogen, Cl_6 alkyl, 25 Cl_6 alkoxy, aryl, halo-aryl, aryloxy, aryl(Cl_6)alkyl, aryl(Cl_6)alkoxy or heteroaryl.
Particular values of R16 include hydrogen, methoxy, phenyl, chlorophenyl, phenoxy, benzyloxy, thienyl, chloro and bromo.
Specific compounds within the scope of the present invention include:

3-(1,2,3,4-tetrahydroisoquinolin-2-yl)methyl-lH-pyrrolo[2,3-b]pyridine;
3-[4-(2-phenylethyl)piperidin-1-yl]methyl-lH-pyrrolo[2,3-35 b]pyridine;

W094/20459 ~ ~S 6 ~l PCT/GB94/00384 3-(4-phenyl-1,2,3,6-tetrahydropyrid-1-yl)methyl-lH-pyrrolo[2,3-b]pyridine;
(E)-3-[4-t2-phenylethenyl)-1,2,3,6-tetrahydropyrid-1-yl]methyl-lH-pyrrolo[2,3-b]pyridine;
3-[4-(2-phenylethyl)-1,2,3,6-tetrahydropyrid-1-yl]methyl-lH-pyrrolo[2,3-b]pyridine:
3-[4-(naphth-2-yl)-1,2,3,6-tetrahydropyridin-1-yl]methyl-lH-pyrrolo[2,3-b]pyridine;
3-[4-(4-methoxyphenyl)-1,2,3,6-tetrahydropyridin-1-yl]methyl-lH-pyrrolo[2,3-b]pyridine;
3-[4-(lH-indol-5-yl)-1,2,3,6-tetrahydropyridin-1-yl]methyl-lH-pyrrolo[2,3-b]pyridine;
3-[4-(benzofuran-5-yl)-1,2,3,6-tetrahydropyridin-1-yl]methyl-lH-pyrrolo[2,3-b]pyridine;
3-[4-(benzofuran-6-yl)-1,2,3,6-tetrahydropyridin-1-yl]methyl-lH-pyrrolo[2,3-b]pyridine;
3-[4-(benzothiophen-2-yl)-1,2,3,6-tetrahydropyridin-1-yl]methyl-lH-pyrrolo[2,3-b]pyridine;
3-[4-(benzofuran-2-yl)-1,2,3,6-tetrahydropyridin-1-yl]methyl-lH-pyrrolo[2,3-b]pyridine;
3-[4-(2-phenylethynyl)-1,2,3,6-tetrahydropyridin-1-yl]methyl-lH-pyrrolo[2,3-b]pyridine;
(E)-3-[4-(2-(thiophen-3-yl)ethenyl)-1,2,3,6-tetrahydropyridin-l-yl]methyl-lH-pyrrolo[2,3-b]pyridine;
(E)-3-[4-(2-(2-chlorophenyl)ethenyl)-1,2,3,6-tetrahydropyridin-l-yl]methyl-lH-pyrrolo[2,3-b]pyridine;
(E)-3-[4-(2-(4-chlorophenyl)ethenyl)-1,2,3,6-tetrahydropyridin-l-yl]methyl-lH-pyrrolo[2,3-b]pyridine;
(E)-3-[4-(2-(thiophen-2-yl)ethenyl)-1,2,3,6-tetrahydropyridin-1-yl]methyl-lH-pyrrolo[2,3-b]pyridine;
3-[4-(2-(furan-2-yl)ethyl)-1,2,3,6-tetrahydropyridin-1-yl]methyl-lH-pyrrolo[2,3-b]pyridine;
3-[4-(2-(tetrahydrofuran-2-yl)ethyl)-1,2,3,6-tetrahydropyridin-l-yl]methyl-lH-pyrrolo[2,3-b]pyridine;
3-[4-(2-(5-methylfuran-2-yl)ethyl)-1,2,3,6-tetrahydropyridin-l-yl]methyl-lH-pyrrolo[2,3-b]pyridine;

W094/20459 5~qlG PCTIGB94/00384 3-(4-ethyl-1,2,3,6-tetrahydropyridin-1-yl)methyl-lH-pyrrolo[2,3-b]pyridine;
3-(4-benzoyloxymethyl-1,2,3,6-tetrahydropyridin-1-yl)methyl-lH-pyrrolo[2,3-b]pyridine;
(E)-3-[4-(2-(3-methoxyphenyl)ethenyl)-1,2,3,6-tetrahydropyridin-1-yl]methyl-lH-pyrrolo[2,3-b]pyridine;
3-(4-phenoxymethyl-1,2,3,6-tetrahydropyridin-1-yl)methyl-lH-pyrrolo[2,3-b]pyridine;
(E)-3-[4-(2-(5-methylfuran-2-yl)ethenyl)-1,2,3,6-tetrahydropyridin-l-yl]methyl-lH-pyrrolo[2,3-b]pyridine;
3-(6-phenyl-1,2,3,4-tetrahydroisoquinolin-2-yl)methyl-lH-pyrrolo[2,3-b]pyridine;
3-(6-methoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)methyl-lH-pyrrolot2,3-b]pyridine;
3-(7-phenyl-1,2,3,4-tetrahydroisoquinolin-2-yl)methyl-lH-pyrrolo[2,3-b]pyridine;
3-(7-benzyloxy-1,2,3,4-tetrahydroisoquinolin-2-yl)methyl-lH-pyrrolo[2,3-b]pyridine;
3-[7-(thiophen-3-yl)-1,2,3,4-tetrahydroisoquinolin-2-yl]methyl-lH-pyrrolo[2,3-b]pyridine;
3-[6-(4-chlorophenyl)-1,2,3,4-tetrahydroisoquinolin-2-yl]methyl-lH-pyrrolo[2,3-b]pyridine;
3-(5-phenyl-1,2,3,4-tetrahydroisoquinolin-2-yl)methyl-lH-pyrrolo[2,3-b]pyridine;
3-(5-benzyloxy-1,2,3,4-tetrahydroisoquinolin-2-yl)methyl-lH-pyrrolo[2,3-b]pyridine;
3-(5-phenoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)methyl-lH-pyrrolo[2,3-b]pyridine:
and salts and prodrugs thereof.
The invention also provides pharmaceutical compositions comprising one or more compounds of this invention in association with a pharmaceutically acceptable carrier. Preferably these compositions are in unit dosage forms such as tablets, pills, capsules, powders, granules, sterile parenteral solutions or suspensions, metered aerosol or liquid sprays, drops, W094/20459 2 ¦ j G ~ ~ PCTIGB94/00384 ampoules, auto-injector devices or suppositories; for oral, parenteral, intranasal, sublingual or rectal administration, or for administration by inhalation or insufflation. Alternatively, the compositions may be presented in a form suitable for once-weekly or once-monthly administration; for example, an insoluble salt of the active compound, such as the decanoate salt, may be adapted to provide a depot preparation for intramuscular injection. For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical carrier, e.g. conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g. water, to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention, or a pharmaceutically acceptable salt thereof. When referring to these preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This solid preformulation composition is then subdivided into unit dosage forms of the type described above containing from 0.1 to about 500 mg of the active ingredient of the present invention. The tablets or pills of the novel composition can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release. A

wog4no4s9 ~ S~ PCTIGB94100384 variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.
The liquid forms in which the novel compositions of the present invention may be incorporated for administration orally or by injection include aqueous solutions, suitably flavoured syrups, aqueous or oil suspensions, and flavoured emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical vehicles. Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinyl-pyrrolidone or gelatin.
In the treatment of schizophrenia, a suitable dosage level is about O.Ol to 250 mg/kg per day, preferably about 0.05 to lO0 mg/kg per day, and especially about 0.05 to 5 mg/kg per day. The compounds may be administered on a regimen of l to 4 times per day.
The compounds in accordance with the present invention may be prepared by a process which comprises reacting a compound of formula III with a compound of formula IV:

W094/20459 2~ PCT/GB94/00384 \~ H - N o l R 5/1\N N
R P

( I I I ) ( I V ) wherein R3, R4 and R5 are as defined above, Q1 represents the residue of a moiety of formula Qa to Qc as defined above, and RP corresponds to the group R as defined above or represents a suitable protecting group; in the presence of a substantially equimolar amount of formaldehyde; followed, where required, by removal of the protecting group RP; and subsequently, if necessary, N-alkylation by standard methods to introduce the moiety R.
The reaction is conveniently carried out by stirring the reactants in aqueous acetic acid, ideally in the presence of a buffer such as sodium acetate trihydrate, suitably at room temperature.
The formaldehyde may be utilised in the form of paraformaldehyde; or as a solution of formaldehyde in an inert solvent, e.g. 37% aqueous formaldehyde.
The protecting group RP, when present, is suitably an acyl moiety such as acetyl, which can conveniently be removed as necessary by treatment under strongly basic conditions, e.g. sodium methoxide in methanol. Alternatively, the protecting group RP may be a carbamoyl moiety such as t-butoxycarbonyl (BOC), which can conveniently be removed as necessary by treatment under mildly acidic conditions.
In an alternative procedure, the compounds according to the present invention may be prepared by a W094/20459 ~/S6~; PCT/GB94/00~84 process which comprises reacting a compound of formula IV
as defined above with a compound of formula V:

45~N\R P

( V ) wherein R3, R4, R5 and RP are as defined above, and L
represents a suitable leaving group; followed, where required, by removal of the protecting group RP: and subsequently, if necessary, N-alkylation by standard methods to introduce the moiety R.
The leaving group L is suitably a halogen atom, e.g. chlorine or bromine; or a dialkylamino group, e.g.
dimethylamino.
When L represents a halogen atom, the reaction between compounds IV and V is conveniently carried out by stirring the reactants under basic conditions in a suitable solvent, for example potassium carbonate in N,N-dimethylformamide, or triethylamine in tetrahydrofuran or acetonitrile. Where L represents a dialkylamino group, the reaction is conveniently effected by heating the reactants in an inert solvent such as toluene, typically at the reflux temperature of the solvent.
Where they are not commercially available, the starting materials of formula III, IV and V may be prepared by procedures analogous to those described in the accompanying Examples, or by standard methods well ~ known from the art.
It will be appreciated that any compound of formula I initially obtained from any of the above processes may, where appropriate, subsequently be W094/20459 ~6 ~ PCT/GB94/00384 elaborated into a further desired compound of formula I
using techniques known from the art. For example, a compound of formula I wherein R is hydrogen initially obtained may be converted into a compound of formula I
wherein R represents Cl_6 alkyl by standard alkylation techniques, such as by treatment with an alkyl iodide, e.g. methyl iodide, typically under basic conditions, e.g. sodium hydride in dimethylformamide, or triethylamine in acetonitrile.
Where the above-described processes for the preparation of the compounds according to the invention give rise to mixtures of stereoisomers, these isomers may be separated by conventional techniques such as preparative chromatography. The compounds may be lS prepared in racemic form, or individual enantiomers may be prepared either by enantiospecific synthesis or by resolution. The compounds may, for example, be resolved into their component enantiomers by standard techniques such as preparative HPLC, or the formation of diastereomeric pairs by salt formation with an optically active acid, such as (-)-di-p-toluoyl-d-tartaric acid and/or (+)-di-p-toluoyl-l-tartaric acid, followed by fractional crystallization and regeneration of the free base. The compounds may also be resolved by formation of diastereomeric esters or amides, followed by chromatographic separation and removal of the chiral auxiliary.
During any of the above synthetic sequences it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protective Grou~s in Orqanic Chemistry, ed. J.F.W. McOmie, Plenum Press, 1973;
and T.W. Greene & P.G.M. Wuts, Protective Groups in Orqanic S~nthesis, John Wiley & Sons, 1991. The 2l~6~l~

protecting groups may be removed at a convenient subsequent stage using methods known from the art.
The following Examples illustrate the preparation of compounds according to the invention.
The compounds useful in this invention potently inhibit [3H]-spiperone binding to human dopamine D4 receptor subtypes expressed in clonal cell lines.

[3H~-Spiperone Binding Studies Clonal cell lines expressing the human dopamine D4 receptor subtype were harvested in PBS and then lysed in 10 mM Tris-HCl pH 7.4 buffer containing 5 mM MgSO4 for 20 min on ice. Membranes were centrifuged at 50,000g for 15 min at 4 C and the resulting pellets resuspended in assay buffer (50 mM Tris-HCl pH 7.4 containing 5 mM EDTA, 1.5 mM CaC12, 5 mM MgC12, 5 mM KCl, 120 mM NaCl, and 0.1%
ascorbic acid) at 20 mg/ml wet weight. Incubations were carried out for 60 min at room temperature (22-C) in the presence of 0.05-2 nM [3H]-spiperone or 0.2 nM for displacement studies and were initiated by addition of 20-100 ~Lg protein in a final assay volume of 0.5 ml. The incubation was terminated by rapid filtration over GF/B
filters presoaked in 0.3% PEI and washed with 10 ml ice-cold 50 mM Tris-HCl, pH 7.4. Specific binding was determined by 10 ,uM apomorphine and radioactivity determined by counting in a LKB beta counter. Binding parameters were determined by non-linear least squares regression analysis, from which the inhibition constant Ki could be calculated for each test compound.
The compounds of the accompanying Examples were tested in the above assay, and all were found to possess a Ki value for displacement of [3H]-spiperone from the human dopamine D4 receptor subtype of below l.S IlM.

2~6~

F~MPT.F, 1 3-(1.2.3.4-Tet.r~ll,ydroi~o~llinolin-2-yl)methYI-lH-pyrrolo r2.3-blDyri~ine 1,2,3,4-Tetrahydroisoql~inoline (1.37g, 10.0mmol) was dissolved in acetic acid (4ml) and water (2ml). 37% Aqueous formaldehyde (0.9ml, 1~mmol) was added and the reaction mixture stirred for five minutes, 1~-pyrrolo[2,3-b]pyridine (1.18g, 9.99mmol) added and the resulting solution stirred at room temperature for 20h. The reaction mixture was poured into 2M aqueous sodium hydroxide solution (50ml) and extracted with ethyl acetate (3 x 50ml). The combined extracts were washed with water (50ml) and brine (50ml). The organic phase was dried (MgSO4) and concentrated in vacuo to give a lemon solid. Recrystallisation from toluene gave the tit~e compound (0.935g, 36%), as an of~-white solid, m.p. 190-192C; (Found: C, 77.51; H, 6.50; N, 15.57. Cl~Hl7N3 requires C, 77.54; H, 6.51; N, 15.96%); ~iH (DMSO-d6) 2.68 (2H, t, J 7.8Hz, CH2), 2.77 (2H, d, J
7.5Hz, CH2), 3.55 (2H, s, CH2), 3.79 (2H, s, CH2), 6.97-7.07 (5H, m, ArH), 7.41 (lH, d, J 1.8Hz, ArH), 8.03 (lH, dd, J 7.8, 1.5Hz, 4-H), 8.20 (lH, dd, J 4.6, 1.5Hz, 6-H), and 11.48 (lH, br s, NH);
m/z (CI+, NH3) 264 (M+1)+.
Prepared in an analogous manner were:
F,XAl~PT.F, 2 3-(4-r2-Phen,ylethyll,piperidin-l-vl)methYl-lH-pyrrolor2.3-bl pyridine.
M.p. 162-163C (PhMe); (Found: C, 79.29; H, 7.97; N, 12.93.
C2lH25N3 requires C, 78.96; H, 7.89; N, 13.15~); ~iH (DMSO-d6) 1.15 (3H, m, 3 x piperidinyl H), 1.48 (2H, m, 2 x piperidinyl H), WO 94/20459 ~ ? it PCT/GB94100384 1.64 (2H, m, CH2CH2Ph), 1.85 (2H, t, J 10.2Hz, 2 ~ piperidinyl H), 2.56 (2H, t, J 8Hz, CH2CH2Ph), 2.83 (2H, d, J 11.2Hz, 2 x piperidinyl H), 3.57 (2H, s, CE2N), 7.02 (lH, dd, J 7.8,4.6Hz, 5-H), 7.12-7.17 (3H, m, ArH), 7.23-7.30 (3H, m, ArH), 8.00 (lH, dd, J 7.8, 1.5Hz, 4-H), 8.80 (lH, dd, J 4.6, 1.5Hz, 6-H), and 11.39 (lH, br s, NH); m/z (CI+, NH3) 320 (M+l)+.

~.X~l~pT.~ 3 3-(4-Phenyl-1.2.3.6-tetr~llydroDyrirlin-l-yl)methyl-lH-pyrrolor2.3-blpyri~ e M.p. 177-179C (MeOH); (Found: C, 78.60; H, 6.80; N, 14.54.
ClgHlgN3 requires C, 78.86; H, 6.62; N, 14.52~ H (DMSO-d6) 2.45 (2H, br 8, CH2), 2.66 (2H, t, J 5.6Hz, CH2), 3.09 (2H, d, J
3.2Hz, CH2), 3.74 (2H, s, C~2N), 6.15 (lH, m, CH), 7.03 (lH, dd, J 7.8, 4.6Hz, 5-H), 7.19-7.26 (lH, m, ArH), 7.30-7.32 (2H, m, ArH), 7.38-7.41 (3H, m, ArH), 8.03 (lH, dd, J 7.8, 1.5Hz, 4-H), 8.19 (lH, dd, J 4.6, 1.5Hz, 6-H), and 11.46 (lH, br 8, NH); m/z (CI+, NH3) 290 (M+l)+.

~X~MPT,F~ 4 (~)-3-(4-r2-PhenylethenYll- 1.2.3.6-tetrahYdropYridin- 1-yl)methvl-lH-pyrrolor2.3-blpyridine A solution of (E)-4-(2-phenylethenyl)-1,2,3,6-tetrahyd~o~yl;dine (204mg, l.lmmol) and 3-dimethylaminomethyl-lH-py-rrolo[2,3-b] pyridine (192mg, l.lmmol) [prepared by the method of M.M. Robison and B.L. Robison, J. Am. Chem. Soc 1955, 77, 457] in toluene (15ml) was stirred under reflux for 24h.

The hot solution was filtered and the filtrate allowed to cool, giving the title compound (196mg, 55%) as a pale brown solid, m.p. 210-212C; (Found: C, 80.43; H, 6.45; N, 13.18. C2lH2lN3O. 0.1PhMe requires: C, 80.31; H, 6.74; N, 12.95~ H (CDCl3) 2.42 (2H, br s, 3 -CH2), 2.72-2.75 (2H, m, 2'-CH2), 3.20 (2H, br s, 6 -CH2), 3.83 (2H, s, C~2N), 5.82 (lH, br s, C~=CR), 6.44 (lH, d, J 16.1Hz, C~I=CHPh), 6.78 (lH, d, J 16.3Hz, CH=C~Ph), 7.07-7.10 (lH, m, 5-H), 7.17-7.21 (lH, m, ArH), 7.26-7.31 (3H, m, ArH), 7.38-7.40 (2H, m, ArH), 8.09 (lH, dd, J 7.9, 1.5Hz, 4-H), 8.31 (lH, dd, J 4.8, 1.5Hz, 4-H), and 9.31 (lH, br s, NH); m/z (CI+, NH3) 316 (M+l)+.

~A~Pr.~ 5 3-(4-Ph~rlylethvl-1 7..3.6-tetral~.l.ou~;tlin-l-yl)Inetllyl-1~-pyrrolor~.3-blpYri~ine M.p. 121-122C (MeOH); (Found: C, 79.06; H, 7.28; N, 13.27. C2lH23N3 requires C, 79.46; H, 7.30; N, 13.24%); ~H
(DMSO-d6) 2.02 (2H, br s, tetrahy~ .yl;dinyl CH2), 2.19 (2H, t, J 7.8Hz, CH2~2Ph) 2.49-2.52 (2H, m, CH2), 2.65 (2H, t, J
8.0Hz, CH2), 2.85 (2H, s, CH2), 3.65 (2H, s, NC~I2Ar), 5.34 (lH, s, C~I=CR), 7.02 (lH, dd, J 7.8, 4.6Hz, 5-H), 7.13-7.19 (3H, m, ArH), 7.23-7.27 (2H, m, ArH), 7.33 (lH, d, J 2.2Hz, 2-H), 7.99 (lH, dd, J 7.8, 1.3Hz, 4-H), 8.18 (lH, dd, J 4.6, 1.5Hz, 6-H), and 11.42 (lH, br s, NH); m/z (CI+, NH3) 318 (M+l)+.

3-(4-NaDhthalen-2-vl-1.2.3.6-tetrahydro~yridin-1-30 yl)methyl-lH-pyrrolor2.3-blpyridine ~VO 94/2WS9 ~ , PCT/GB94tO0384 SteD 1: 1-(4-Hydroxv-4-na~hthalen-2-vl-pi~eridin-1-yl)ethanone 2-Bromonaphthalene (24.75g, 0.12mol) in tetrahydrofuran (180ml) was slowly added to m~gne~sium (2.9g, 0.12mol) in tetrahydrofuran (20ml) and the mixture stirred at room temperature for one hour. The resultant solution was slowly added to 1-acetyl-4-piperidone (16.9g, 0.12mol) in tetrahydrofuran (200ml) at -78C, and then allowed to stir to room temperature. The white suspension formed was hydrolysed with hydrochloric acid (120ml, lM) and the organic layer removed and co~centrated in vacuo. The residue was taken up in dichloromethane, dried (MgSO4), and concentrated to leave a clear oil. Trituration of this oil ~,vith diethyl ether gave 1-(4-hydl o~y-4-naphthalen-2-yl-piperidin- l-yl)ethanone (13.92g, 43~o) as a white solid; OH (CDCl3) 1.90 (4H, m, 2 x piperidinyl CH2), 2.10 (2H, m, piperidinyl CH2), 2.15 (3H, s, COC~3), 3.20 (lH, m, piperidinyl H), 3.70 (lH, m, piperidinyl H), 4.60 (lH, br m, OH), 7.50 (2H, m, ArH), 7.60 (lH, dd, J 9.6, 1.6Hz, ArH), and 7.90 (4H, m, ArH).

Step 2: 4-NaDhthalen-2-vl-1.2.3~6-tetrahydropyridine 1-(4-Hydroxy-4-naphthalen-2-yl-piperidin-1-yl)ethanone (3.40g, 13mmol) was dissolved in hydrochloric acid (50ml, 6M) and the solution refluxed for 12 hours. The resultant mixture was cooled in ice, basified with sodium hydroxide solution (32ml, 10M) and extracted with dichloromethane (2 x 100rnl). The extracts were combined, dried (MgSO4) and concentrated to give 4-naphthalen-2-yl-1,2,3,6-tetrahydropyridine (2.12g, 78%) as a tan solid; ~H (CDCl3) 2.60 (2H, m, tetrahydropyridinyl CH2), 3.20 6 ~

(2H, t, J 5.6Hz, tetrahy~o~yl;dinyl CH2), 3.60 (2H, m, tetrahydropyridinyl CH2), 6.30 (lH, m, C.~=CR), 7.45 (2H, m, ArH), 7.60 (lH, dd, J 8.4, 1.4Hz, ArH), and 7.80 (4H, m, ArH).

~te~ 3: 3-(4-N~Dhth~len-~-y~ 2~3~6-tetr~hydro~yri~lin yl)rnet,hvl-l~-Dyrrolor~.3-bl~yri~ine 4-Naphthalen-2-yl-1,2,3,6-tetrahydropyridine (597mg, 2.9mmol) was reacted with 3-dimethyl~minomethyl-lH-pyrrolo[2,3-b]pyridine (500mg, 2.9mmol) as exemplified in ~mrle 4 to give the tit~e compound (619mg, 63%) as tan crystals, m.p. 223-225C (EtOH); (Found: C, 81.05; H, 6.24; N, 12.19. C23H2lN3 requires C, 81.38; H, 6.24; N, 12.38%); OH
(DMSO-d~) 2.60 (2H, m, tetrahy~ yl;dinyl CH2), 2.72 (2H, t, J

5.7Hz, tetrahy~ .yl;dinyl CH2),3.16 (2H, d, J 2.7Hz, tetrahyLol,yl;dinyl CH2), 3.78 (2H, s, ArC~2N), 6.34 (lH, m, C~=CR), 7.04 (lH, dd, J 7.5, 1.5Hz, 5-H), 7.40 (lH, d, J 2.3Hz, ArH), 7.44 (2H, m, ArH), 7.66 (lH, dd, J 1.6, 7.8Hz, ArH), 7.86 (4H, m, ArH), 8.06 (lH, d, J 7.6Hz, 4-H), 8.20 (lH, d, J 1.5Hz, 6-H), and 11.48 (lH, br s, NH); m/z (CI+, NH3) 340 (M+l)+.

F~XAl~PT,h~ 7 3-(4-r4-Methoxy~henvll-1.2.3.6-tetrahydropvridin-1-25 yl)methvl-lH-~yrrolor2.3-blpvridine ~ 5te~ 1: 1-(4-Hydroxv-4-r4-methoxvE)henyll-~ eridin-1-yl)ethanone 4-Bromoanisole (22.4g,0.12mol) in tetrahydrofilran (180ml) was slowly added to magnesium (2.9g, 0.12mol) in ~0 tetrahydrofuran (20ml) and the mixture stirred for one hour at room temperature. The solution formed was slowly added to a solution of 1-acetyl-4-piperidone (16.9g, 0.12mol) in tetrahyLo`u.an (200ml) at -78C, and the suspension produced was stirred to room temperature for 2 hours. Hydrochloric acid (120ml, lM) was added and the organic phase was separated and cor centrated in vacuo. The residue was taken up in dichloromethane (300ml), washed with water (300ml) and dried (MgSO4). Concentration in vacuo and trituration with diethyl ether gave 1-[4-hyd~,xy-4-(4-methoxyphenyl)-piperidin-1-yl]eth~none (14.75g, 50% yield) as a white solid; ~iH (CDCl3) 1.7-2.1 (4H, m, 2 x piperidinyl CH2), 2.1 (3H, s, COC~3), 3.1 (lH, m, piperidinyl H), 3.6-3.8 (3H, m, piperidinyl H), 3.8 (3H, s, ArOC~3), 4.6 (lH, m, OH), 6.9 (2H, d, J 10Hz, ArH), and 7.4 (2H, d, J 10Hz, ArH).

~tep 2: 4-(4-Methoxyphenyl)-1.~.3.6-tetr~ lro~ line 1-(4-Hydroxy-4-[4-methoxyphenyl]piperidin-1-yl)et~none (14.75g, 59mmol) was dissolved in hydrochloric acid (250mg, 6M) and refluxed for 12 hours. The reaction milrtllre was cooled in ice and basified with sodium hydroxide solution (155ml, 10M), then extracted with dichloromethane (2 x 500ml). The extractions were combined, dried (MgSO4), and concentrated in vacuo. The crude product was purified by flash chromatography eluting with 10% methanol in dichloromethane, cont~ining 1%
aqueous a~nmonia. Concentration of the appropriate fractions gave 4-(4-methoxyphenyl)-1,2,3,6-tetrahydropyridine (2.65g, 24%) as a tan solid; ~iH (DMSO-d6) 2.3 (2H, m, tetrahydropyridinyl CH2), 2.9 (2H, t, J 5.6Hz, tetrahydropyridinyl CH2), 3.4 (2H, d, J 3.4Hz, WO 94/20459 21~ ~ 4 10 PCT/GB94/00384 tetrahydropyridinyl CH2), 3.7 (3H, s, ArOC~3), 6.1 (lH, m, C_=CR), 6.9 (2H, d, J 9.6Hz, ArH), 7.3 (2H, d, J 9.6Hz, ArH), and 9.6 (lH, br s, NH).

~te~ 3: 3-(4-r4-Metho~ypher~yll-1~.3.6-tetr~llyd.o~yL;~in-l-yl)rnet.~,yl-lH-pyrrolor~.3-blpyri~line 4-(4-Methoxyphenyl)-1,2,3,6-tetrahydropyridine (540mg, 2.8mmol) was reacted with 3-dimethyl~minomethyl-1H-pyrrolo[2,3-b]pyridine (500mg, 2.8mmol) as in Example 4 to give the title compound (367mg, 41~o) as tan crystals, m.p. 202-204C
(iPrOH); (Found: C, 73.51; H, 6.74; N, 12.15. C2oH2lN30Ø33 H20Ø2 C3H80 requires C, 73.34; H, 6.95; N, 12.45~ iH
(DMSO-d6) 2.44 (2H, m, tetrahyd~o~yl;dinyl CH2), 2.70 (2H, m, tetrahyLo~y~;dinyl CH2), 3.10 (2H, m, tetrahy~Lo~yl;dinyl CH2), 3.74 (3H, s, ArOC~3), 3.76 (2H, s, ArC~2N), 6.04 (lH, m, C~=CR), 6.90 (2H, d, J 8.6Hz, ArH), 7.04 (lH, dd, J 7.7, 4.6Hz, 5-H), 7.36 (2H, d, J 8.5Hz, ArH), 7.40 (lH, s, 2-H), 8.06 (lH, d, J
7.7Hz, 4-H), 8.20 (lH, d, J 4.6Hz, 6-H), and 11.48 (lH, br s, NH);
m/z (CI~, NH3) 320 (M+1)~.

EXAMPT.~ 8 3-(4-r1H-Indol-5-Yll-1.2.3.6-tetrahydropyridin-1-vl)methyl-1H-pyrrolor2.3-blpyridine Step 1: 5-Bromo-l-triisopropylsilyl-lH-indole 5-Bromoindole (14.04g, 72mmol) in tetrahydrofuran 30 (50ml) was added dropwise to a suspension of sodium hydride (60% dispersion in oil; 3.04g, 76mmol) in tetrahydrofuran WO 94/20459 ~ PCT/GB94/00384 ~C~lD

(lOOml) and the resultant solution stirred for one hour at room temperature. Triisopropylsilyltrifluoromethane sulphonate (23.3g, 76mmol) was added slowly and the solution stirred for a further one hour. The reaction _ixture was washed with sodium 5 hydrogen carbonate solution, dried (MgSO4), and concentrated.
The crude ...;Y l ~. e was purified by flash chromatography, with heY~ne as eluant, to give 5-bromo-1-triiso~ro~ylsilyl-1H-indole (20.0g, 79%) as a clear oil; ~H (CDCl3) 1.10 (18H, d, J 8.4Hz, 6 x CH3), 2.70 (3H, m, 3 x CH), 6.55 (lH, d, J 3.9Hz, ArH), 7.20 (2H, m, ArH), 7.35 (lH, d, J 8.5Hz, ArH), and 7.75 (lH, d, J 1.4Hz, ArH).

~;tep 2: l-r4-Hy-lroxy-4-(1-triisopro~vlsilyl- lH-indol-5-yl)~iperi~lin-1-yllet.h~none 5-Bromo-1-triiso~, ol~ylsilyl-1H-indole (13.7g, 38.9mmol) in tetrahydrofuran (250ml) at -78C was treated with t-butyllithium (45.8ml, 77.8mmol, 1.7M solution in per t~nes) and stirred at this temperature for 15 minutes. The yellow solution formed was added to 1-acetyl-4-piperidone (5.49g, 38.9mmol) in tetrahydrofuran (250ml) at -78C, and the mixture allowed to warm to room temperature. Hydrochloric acid (40ml, lM) was added and the mixture extracted with ethyl acetate (2 x 500ml).
The extracts were combined, dried (MgSO4) and concentrated.
The crude product was purified by flash chromatography using ethyl acetate as eluant, to give 1-[4-hydroxy-4-(1-triisopropylsilyl-lH-indol-5-yl)piperidin-1-yl]ethanone (3.39g, 21%) as a white solid; ~H (DMS-d6) 1.10 (18H, d, J 7.9Hz, 6 x CH3), 1.70 (3H, m, 3 x CH), 2.00 (2H, m, piperidinyl H), 2.05 (3H, s, COC~), 2.45 (lH, m, piperidinyl H), 3.00 (lH, m, piperidinyl H), 3.30 (lH, m, piperidinyl H), 3.50 (lH, m, 2 ~

piperidinyl H), 3.70 (lH, m, piperidinyl H),4.30 (lH, m, piperidinyl H), 5.00 (lH, 8, OH), 6.60 (lH, d, J 2.8Hz, ArH), 7.30 (lH, d, J 7.8Hz, ArH), 7.35 (lH, d, J 2.2Hz, ArH), 7.50 (lH, d, J
7.9Hz, ArH), and 7.70 (lH, s, ArH).

~ tep 3: 1-(4-rl-Trii~v~ovylci~ I-indol-5-y~ 3~6 tetral~ o~.yl ;~in-l-yl)eth~none 1-(4-Hydroxy-4-[1-triisopropylsilyl- lH-indol-5-yl]-piperidin-l-yl)ethanone (3.11g, 7.4mmol) in dichloromethane (lOOml) was treated with pyridinium p-toluenesulfonate (3.8g, 15.1mmol) and stirred for 72 hours. The solution was poured into water and extracted with dichloromethane (lOOml). The extractions were dried (MgSO4), concPntrated and the crude product purified by flash chromatography using ethyl acetate as eluant, to give 1-(4-[1-triiso~ ylsilyl-lH-indol-5-yl]-1,2,3,6-tetrahy~o~ylidin-l-yl)-eth~none (1.95g, 66%) as a white solid;
~iH (CDCl3) 0.80 (18H, d, J 8.5Hz, 6 x CH3), 1.30 (3H, m, 3 x CH), 1.75 (3H, d, J 6.7Hz, COCH3), 2.30 (2H, m, tetrahydropyridinyl H), 3.25 (lH, t, J 5.6Hz, tetrahyd~o~y~idinyl H), 3.40 (lH, t, J
5.6Hz, tetrahydlol yl;dinyl H), 3.75 (lH, m, tetrahydropyridyl H), 3.85 (lH, m, tetrahydropyridyl H), 5.60 (lH, m, CH=CR), 6.20 (lH, d, J 2.2Hz, ArH), 6.80 (2H, m, ArH), 7.00 (lH, d, J

7.3Hz, ArH), and 7.20 (lH, m, ArH).
Step 4: 5-(1.2.3.6-Tetrah~dro~ridin-4-yl~-lH-indole 1-(4-[1-Triisopropylsilyl-lH-indol-5-yl]-1,2,3,6-tetrahydro-2H-pyridin-l-yl)ethanone (1.96g,4.9mmol) was dissolved in methanol (70ml), treated with potassium hydroxide solution (35ml, 40%), and the mixture heated at 60C for 12 hours. The 2ls64lo re~ction mixture was cooled, extracted with ethyl acetate (2 x 100ml), and the extracts were comhined, dried (MgSO4), and concentrated. The crude product was purified by flash chromatography on silica, using 10% methanol in 5 dichloromethane cont~inin~ 1% ~mmorli~ as eluant, to give 5-(1,2,3,6-tetrahydropyridin-4-yl)-lH-indole (619mg, 64%) as a yellow solid; OH (CDC13) 2.10 (2H, m, tetrahyLol.yl;dinyl CH2), 2.60 (2H, m, tetrahydropyridinyl CH2), 3.00 (2H, m, tetrahydropyridinyl CH2), 5.50 (lH, m, C~=CR), 5.90 (lH, s, ArH), 6.60-7.10 (4H, m, ArH).

~ ;tep 5: 3-(4-r1H-Indol-5-vll-1.2.3.6-tetr~l~ydropvri~in-1-yl~rnet.hvl-lH-pyrrolor2.3-blpyrirline 5-(1,2,3,6-Tetrahy~L~o~yl;din-4-yl)-lH-indole (200mg, 1.01 mmol) and 3-dimethyl~minomethyl-lH-pyrrolo[2~3-b]pyridine (177mg, 1.01mmol) were coupled as described in ~Y~mple 4 to give a solid which was purified by flash chromatography, eluting with 10% methanol in dichloromethane 20 cont~inin~ 1% ~mmoni~. Recryst~ tio~ frommethanol gave the title compound (115mg, 35%) as a tan solid, m.p. 187-189C;
(Found: C, 73.78; H, 6.34; N, 16.13. C21H2oN4Ø75 H2O requires C, 73.77; H, 6.34; N, 16.39%); OH (DMSO-d6) 2.68 (2H, m, tetrahydropyridinyl H), 3.10 (2H, s, tetrahydropyridinyl H), 3.18 25 (lH, d, J 4.4Hz, tetrahydlo~yl;dinyl H), (other tetrahydropyridinyl H obscured by solvent at 3.30), 3.74 (2H, s, ArCH2N), 6.02 (lH, m, CH=CR), 6.40 (lH, s, ArH), 7.04 (lH, dd, J 7.5, 3.2Hz, 5-H), 7.20 (lH, d, J 8.2Hz, ArH), 7.32 (2H, m, ArH), 7.40 (lH, s, ArH), 7.52 (lH, s, ArH), 8.04 (lH, d, J 7.5Hz, 4-H), WO 94/20459 4~ ~3 PCT/GB94/00384 8.18 (lH, d, J 3.2Hz, 6-H), 11.00 (lH, br s, NH), and 11.48 (lH, br s, NH); m/z (CI~ NH3) 329 (M+1)~.
F~XAl\~PT.F. 9 3-(4-Re~7.ofilr~n-5-v~ 3~6-tetr~llydro~yridi 5 yl)methyl-1~-pvrrolor2.3-blDyrir~ine ~ tep 1: 5-Bromobenzofuran A solution of 4-bromophenol (17.3 g, 100 mmol) in dimethylformamide (40 ml) was treated with bromoacetaldehyde dimethyl acetal (16.9 g, 100 mmol) and potassium carbonate (13.8 g, 100 mmol) and heated at 150 C for 16 h. The mixture was cooled, poured into water (500 ml) and extracted with diethyl ether (3 x 100 ml). The comhine-l organic extracts were dried (MgSO4), concentrated, and filtered through a plug of silica gel eluting with 10% diethyl ether in he~ne. The resulting oil ( 15 g) was added to a solution of polyphosphoric acid (~12 g) in toluene (100 mL) and heated at 80 C for 16 h. The mixture was cooled and the toluene layer was dec~nte-l off and washed with saturated aqueous sodium hydrogen carbonate, dried (MgSO4), concentrated and the residue distilled to give 5-bromobenzofuran -(6 g) as a colourless oil, bp. 98C /1 mmHg; H (DMSO-d6) 6.96 (lH, m, ArH), 7.45 (lH, m, ArH), 7.59 (lH, m, ArH), 7.91 (lH, m, ArH), and 8.05 (lH, m, ArH).
Step 2: 1-(4-Benzofuran-5-yl-4-hvdroxypiperidin-1-yl)ethanone The Grignard of 5-bromobenzofuran (1.54 g, 7.8 mmol) was prepared from m~gne~ium (209 mg, 8.6 mmol) in tetrahydrofuran ( 10 ml), initiating the reaction with 1,2-9 ~ PCT/GB94/00384 ~s64l~

dibromoethane. The Grignard was added to a solution of N-acetyl-4-piperidone (1.21 g, 8.6 mmol) in tetrahydrofuran at -78C resulting in a thick precipitate. The mixture was warmed to room temperature~ digested with 2 M hydrochloric acid (lOml) and extracted with dichloromet~n~ (3 x 50ml). The comhine-l organic extracts were dried (MgSO4), concentrated, and purified by flash chromatography, eluting with ethyl acetate, to give the title product as a colourless oil (750 mg); ~iH (DMSO-d6) 1.66 (lH, m, piperidinyl H), 1.80 (lH, m, piperidinyl H), 2.03 (lH, m, piperidinyl H), 2.04 (3H, s, CH3CO), 2.95 (lH, m, piperidinyl H), 3.30 (lH, m, piperidinyl H), 3.40 (lH, m, piperidinyl H), 3.70 (lH, m, piperidinyl H), 4.32 (lH, m, piperidinyl H), 5.14 (lH, s, OH), 6.93 (lH, m, ArH), 7.44 (lH, m, ArH), 7.51 (lH, m, ArH), 7.75(1H,m,ArH),and7.95(1H,m,ArH).
~teD 3: 4-~n7.ofilr~n-5-vl-1.~.3.6-tetr~hydropvri~line A solution of 1-(4-benzofuran-5-yl-4-hydlo~y~i~eridin-1-yl)et~nor~e (650 mg, 2.51 mmol) in tetrahydrofuran (lOml) was treated with 6 M HCl (10 mL) and heated at 60 C for 16 h. The mixture was poured into saturated aqueous sodium hydrogen carbonate (100ml) and extracted with CH2Cl2 (3 x 100ml). The colnhine-l organic extracts were dried (MgSO4) and concentrated to give the title product (220 mg) as a semi-solid; ~H (DMSO-d6) 1.4 - 3.7 (6H, 3 x CH2), 6.16 (lH, m, C;~=CR), 6.95 (lH, m, ArH), 7.45 (lH, m, ArH), 7.59 (lH, m, ArH), 7.72 (lH, m, ArH), and 7.99 (lH, m, ArH).
Ste~ 4: 3-(Benzofuran-5-v~ 2~3~6-tetrahydropyridin yl )methyl- lH-pyrrolor2.3-bl~yridine A suspension of 7-azagramine (180 mg, 1.0 mmol) and 4-benzofuran-5-yl-1,2,3,6-tetrahydropyridine (200 mg, 1.0 mmol) in toluene (5ml) was heated at 110 C for 16 h. The resulting hot solution was filtered and allowed to cool. The title compound (180 mg) cryst~lliRe~l and was collected by filtration as a white, crystalline solid, m.p. 16~70C; (Found: C, 75.02; H, 5.81; N, 12.28. C2lHlgN3OØ33.H2O requires C, 75.20; H, 5.91; N, 12.53); loH (DMSO-d6) 2.50 (2H, br s, tetrahydropyridinyl CH2, obscured by solvent), 2.69 (2H, br s, CH2), 3.11 (2H, br s, tetrahydropyridinyl CH2), 3.76 (2H, s, ArC~2N), 6.12 (lH, br s, C~=CR), 6.91 (1H, s, ArH), 7.03 (1H, m, ArH), 7.40 (2H, m, ArH), 7.51 (lH, m, ArH), 7.64 (lH, s, ArH), 7.95 (lH, m, ArH), 8.04 (lH, m, ArH), 8.20 (lH, m, ArH), and 11.47 (lH, br s, NH);
m/z (CI+, NH3) 330 (M+H)+.
F~XAl~IPT F' 10 3-(4-Benzofuran-6-yl-1.2.3.6-tetrahydro~yl idin-1-yl)methyl-lF~-pyrrolor2.3-blpvridine A suspension of 7-azagramine (551 mg,3.15 mmol) and a 1: 1 mi~tllre of 4-benzofuran-6-yl-1,2,3,6-tetrahydropyridine and 4-benzofuran-4-yl-1,2,3,6-tetrahydropyridine (645 mg, 3.24 rnmol, produced from 3-bromophenol following the analogous procedure described in Example 9) in toluene (10ml) was heated at 110 C for 16 h. The resulting hot solution was filtered and cooled. An isomeric mixture of products crystallised from solution and was collected by filtration as a white crystalline solid. The title compound was isolated pure as its trifluoroacetate salt (60 mg) by preparative reversed phase HPLC (C1g column, eluting with 30% MeCN in 1% aqueous trifluoroacetic acid, required product is the faster eluting of the ~s6~

two products), m.p. 161 - 163 C (Et2O); (Found: C, 59.73; H, 4.35; N, 9.13. C2lHlgN30.CF3CO2H.H20 requires C, 59.87; H, 4.81; N, 9.11); ~iH (DMSO-d6) 2.86 (2H, br s, tetrahydropyridinyl CH2), 3.38 (lH, m, tetrahydropyridinyl H), 3.74 (lH, m, tetrahyd~vl,yl;dinyl H), 3.89 (2 H, br s, tetrahydloyyl;dinyl H), 4.60 (2H, br s, ArC~2N), 6.25 (lH, br 8, C~=CR), 6.95 (lH, s, ArH), 7.21 (lH, m, ArH), 7.40 (lH, m, ArH), 7.64 (lH, m, ArH), 7.70 (lH, s, ArH), 7.76 (lH, br s, ArH), 8.00 (lH, br s, ArH), 8.25 (lH, m, ArH), 8.31 (lH, m, ArH), and 9.88 (lH, br s, NH+), and 12.07 (lH, bs, NH); m/z (CI+, NH3) 330 (M+H)+.
~X~MPT.F: 11 3-(4-rRenzothiophen-2-yll-1.2.3.6-tetr~ydropyri~lin-1-yl)methvl-lH-pyrrolor~.3-blpyritline ~teD 1: l-Ren7~y1-4-(benzothiophen-2-yl)-1 ~.3.6-tetr~h vll. ouy~ ;tline To a solution of benzothiophene (3g, 22.4mmol) in anhydrous tetrahydrofuran (50ml) at -10C under nitrogen was added n-butyllithium (9.83ml of a 2.5M solution in toluene), the miYtllre was allowed to warm to room temperature and stirred for 1 hr. The reaction mixture was cooled to -40C and l-benzyl-4-piperidone (4.23g, 22.4mmol) added, allowed to warm to room temperature and stirred for 14 hr. The reaction mixture was concentrated in uacuo and trifluoroacetic acid (lOml) added.
This mixture was stirred at room temperature for 14 hr and then concentrated in uacuo. The product was extracted into dichloromethane (3 x lOOml) from aqueous potassium carbonate.
The organic layer was washed with water (1 x 50ml), brine (1 x WO 94/20459 ~6~ ) PCT/GB94/00384 50ml) and dried (MgSO4). After con~entration of the extracts the crude product was purified using silica gel column chromatography to yield the title compound (4.2g, 68~o) as a colourless oil; OH (CDC13) 2.64 (2H, m, tetrahydropyridinyl CH2), 2.74 (2H, m, tetrahy~Lol~ylidinyl CH2), 3.18 (2H, m, tetrahydropyridinyl CH2), 3.65 (2H, s, PhC~2N), 6.18 (lH, m, C~=CR), 7.11 (lH, s, 3'-H), and 7.24-7.73 (9H, m, Ar-H).

~teD 2: 4-(Rer~othiophen-2-yl)-1.2.3.6-tetrahvdro~yri~line Hv-lro~hloride To a solution of 1-benzyl-4-(benzothiophen-2-yl)-1,2,3,6-tetrahydropyridine (4g, 13.1mmol) in anhydrous dicbloromethane (50ml) at 0C under nitrogen was added 2-chloroethylchloroformate (1.84ml, 17.0mmol) and the mixture stirred for 1 hr. The reaction mixture was cor centrated in vacuo and methanol (20ml) added and the solution heated to reflux for 1 hr. After cooling the tLtle compound was collected by filtration (2.2g, 67%), m.p. 269C (dec.).
~te~ 3: 3-(4-(Berl~othioI~hen-2-vl)-1.2.3.6-tetr~ydro~yridin- 1-yl )methyl- 1H-~yrrolor2.3-bl~vridine Reaction of 3-dimethylaminomethyl- lH-pyrrolor2,3-b]pyridine and 4-(benzothiophen-2-yl)-1,2,3,6-tetrahydlo~ ;dine in an analogus manner to Example 4 gave the title compound, m.p. 241-246C (dec.); (Found: C, 72.85; H, 5.54; N, 12.06;
C2lHlgN3S requires C, 73.01; H, 5.54; N, 12.16%); ~H (DMS-d6) 2.51 (2H, br s, tetrahydropyridinyl CH2), 2.67 (2H, m, tetrahydropyridinyl CH2), 3.14 (2H, m, tetrahydropyridinyl CH2), 3.76 (2H, s, CH2N), 6.19 (lH, br s, CH=CR), 7.03 (lH, m, VVO 94/20459 2~6g~ PCT/GB94/00384 ArH),7.31(2H,m,3'-HandArH),7.74(1H,d,J8Hz,ArH),7.86 (lH, d, J 8Hz, ArH), 8.05 (lH, d, J 8Hz, ArH), 8.20 (lH, m, ArH), and 11.45 (lH, br s, NH); m/z (CI~, NH3) 346 (M+1)~.

~XA~IPr ~ 12 3-(4-rRen7.ofilr~n-~-vll- 1.~.3.4-tetr~l~ydro~yrirlin- 1-yl)methyl~vrrolor2.3-blpYridine ~teD 1: 4-(Ren7ofi~r~n-2-v~ -benzyl-4-hvdroxyDiDeri~line To a solution of benzofuran (4g, 33.9mmol) in tetrahydrofuran (90ml) at -10C was slowly added a solution of n-butyllithium (2.5M in h~Y~n.os, 13.6ml, 34mmol), keeping the temperature at -10C. The reaction was stirred and allowed to warm to room temperature over 1 hr, after which a solution of 1-benzyl-4-piperidone (6.3ml, 34mmol) in tetrahydrofuran (30ml) was added d~o~wise. Stirring was continued for 2 hr at room temperature. The solvent was evaporated and the residue partitioned between saturated aqueous sodium carbonate (75ml) and ethyl acetate (3 x 100ml). The comhined organics were dried (MgSO4) and evaporated. The residue was purified by column chromatography, eluting with ethyl acetate, to give 4-(benzofuran-2-yl)-1-benzyl-4-hydroxypyridine (7.5g, 75%); aH
(CDCl~) 1.96-2.00 (2H, m, piperidinyl CH2), 2.21-2.29 (2H, m, piperidinyl CH2), 2.44 (lH, t, J 6.2Hz, piperidinyl CH), 2.56 (2H, dt, J 11.1, 2.7Hz, piperidinyl CH2), 2.64-2.68 (3H, m, piperidinyl CH2, OH), 2.73 (lH, t, J 6.2Hz, piperidinyl CH), 3.55 (2H, s, PhCH2N), 6.58 (lH, s, 3'-H), 7.19-7.34 (7H, m, ArH), 7.44 (lH, d, J 7.3Hz, ArH), and 7.52 (lH, d, J 6.6Hz, ArH).

W0 94/20459 ~ PCT/GB94/00384 ~;tep 2: 2-(1-P~en7vl-1.2.3.6-tetrahydropyridin-4-yl)benzofur~n A mixture of the preceding alcohol (2g, 6.5mmol) and 4-toluenesulfonic acid monohydrate (1.2g, 6.6mmol) in toluene (lOOml) was refluxed under Dean and Stark conditions for 2 hrs.
The solvent was evaporated, and the residue partitioned between dichloromethane (3 x lOOml) and saturated aqueous sodium carbonate (lOOml). The comhined organics were dried (MgSO4) and evaporated to yield the t~t~e compound (1.2g, 64%).
An analytical sample was recrystallised from ether to give 2-(1-benzyl-1,2,3,4-tetrahydro~y,;din-4-yl)benzofuran, m.p. 139-140C; (Found: C, 82.40; H, 6.43; N, 4.67. C20HlgNOØ1H20 requires C, 82.50; H, 6.65; N, 4.81%); OH (CDCl3) 2.55 (2H, br s, tetrahyLo~yl;dinyl CH2), 2.74 (2H, t, J 5.7Hz, tetrahydrol.y,;dinyl CH2), 3.24 (2H, br s, tetrahydropyridinyl CH2), 3.67 (2H, s, NC~2Ph), 6.48-6.52 (2H, m, tetrahydropyridinyl 5-CH, 3'-H), 7.14-7.42 (8H, m, ArH), and 7.49 (lH, d, J 7.5Hz, ArH); m/z (CI~, NH3), 290 (M~
~tep 3: 4-(Ren7:ofllr~n-2-yl)-1.2.3.6-tetrahvdro~vridine To a solution of the foregoing tetrahydropyridine (1. lg, 3.8mmol) in dichloromethane (50ml) at 0C was added 1-chloroethylchloroformate (493~1, 4.6mmol), keeping the temperature below 0C. The reaction was allowed to warm to room temperature over 1 hr, after which the solvent was evaporated. Methanol (50ml) was added to the residue and the mixture heated under reflux for 2 hrs. The solvent was removed by evaporation, and the residue chromatographed on silica, eluting with dichloromethane/methanol/ammonia (90:10:1), to WO 94/20459 2~,~. PCT/GB94/00384 yield the title compound as a buf~ solid (600mg, 79%); ~H (CDCl3) 2.44-2.48 (2H, m, tetrahydropyridinyl CH2), 3.14 (2H, t, J 5.8Hz, tetrahydropyridinyl CH2), 3.60-3.63 (2H, m, tetrahydrol y,idinyl CH2), 6.54-6.58 (2H, m, C~=CR, 3'-H), 7.16-7.26 (2H, m, 5'-H, 6'-H), 7.42 (lH, d, J 7.8Hz, 7'-H), and 7.50 (lH, d, J 7.2Hz, 4'-H).

~ teD 4: 3-(4-rP~en~ofilr~n-~-yl-1 ~.3.6-tetr~l~y~lro~yrirlin-1-yl)lnethyl~vrrolor2.3-bl~yridine Prepared from 4-(benzofuran-2-yl)-1,2,3,6-tetrahyLo~ dine by the method outlined in Example 4; m.p.
202-204C (DMF/MeOH); (Found: C, 76.12; H, 5.78; N, 12.46.
C2lHlgN3OØ1H2O requires C, 76.16; H, 5.84; N, 12.69%); ~H
(DMSO-d6) 2.46 (2H, br s, tetrahyd~yl;dinyl CH2), 2.68 (2H, t, J 5.6Hz, tetrahyLo~y,;dinyl CH2), 3.16 (2H, br 8, tetrahy~ol~yHdinyl CH2), 3.77 (2H, s, NCH2Ar), 6.44 (lH, br 8, tetrahy~Lo~yHdinyl 5-CH), 6.78 (lH, 8, 3'-H), 7.01-7.05 (lH, m, ArH), 7.19-7.27 (2H, m, ArH), 7.40 (lH, s, 2-H), 7.50 (lH, d, J
8.3Hz, ArH), 7.57 (lH, d, J 8.3Hz, ArH), 8.04 (lH, dd, 7.8, 1.2Hz, 4-H), 8.20 (lH, dd, J 4.6, 1.5Hz, 6-H), and 11.48 (lH, br 8, NH); m/z (CI+, NH3) 330 (MH)+.

3-r4-Phenvlethynyl- 1.2.3.6-tetrahvdro~yridin- 1-yllmethylpyrrolor2.3-blpyridine M.p. 198-200C (MeOH); (Found: C, 80.23; H, 6.01; N, 13.03. C2lHlgN3 requires C, 80.48; H, 6.11; N, 13.41%); ~H
(DMSO-d6) 2.25 (2H, br s, tetrahydropyridinyl CH2), 2.58 (2H, t, J 5.6Hz, tetrahydropyridinyl CH2), 3.16-3.17 (2H, m, 2~&~ ~

tetrahydropyridinyl CH2), 3.73 (2H, s, NC~2Ar), 6.14 (lH, br s, tetrahyd~ol.yl;dinyl 6-CH), 7.02-7.05 (lH, m, ArH), 7.34-7.42 (6H,m,ArH),8.02(1H,d,J6.5Hz,ArH),8.19(1H,dd,J4.7, 1.6Hz, 6-H), and 11.44 (lH, br ~, NH); mJz (CI~, NH3) 314 (M+l)t.

~AMPT h~ 14 (0-3-(4-r2-(Thien-3-yl)ethenyll-1.2.3.6-tetr~ydropyridin-l-yl)met~ olor2.3-blpyrirline M.p. 215-217C (MeOH); (Found: C, 71.15; H, 5.92; N, 12.78. ClgHlgN3S requires C, 70.99; H, 5.96; N, 13.07%); ~H
(DMSO-d6) 2.26 (2H, br 8, tetrahy~ l;dinyl CH2), 2.61 (2H, t, J 5.6Hz, tetrahy~ ,yl;dinyl CH2), 3.05 (2H, br 8, tetrahyL~l yl;dinyl CH2), 3.72 (2H, s, NC~2Ar), 5.81 (lH, br s, tetrahydlo~yl;dinyl 5-CH), 6.47 (lH, d, J 16.2Hz, CC~=CH), 6.72 (lH, d, J 16.2Hz, CH=CEAr), 7.01-7.04 (lH, m, ArH), 7.33-7.37 (2H, m, ArH), 7.42 (lH, br s, ArH), 7.48-7.50 (lH, m, ArH), 8.02 (lH, d, J 6.7Hz, ArH), and 8.19 (lH, dd, J 4.6, 1.4Hz, 6-H);
m/z (CI~, NH3) 322 (M+l)~, 339 (M+NH4~).

(~)-3-(4-r2-(2-Chlorophenyl)ethenyll-1.2.3.6-tetr~llydropyridin-l-yl)methYlpyrrolor2.3-bl~yridine M.p. 174-176C (xylene); (Found: C, 71.38; H, 5.62; N, 11.70. C2lH20ClN3Ø2H2O requires C, 71.36; H, 5.82; N, 11.89%);
~H (DMSO-d6) 2.31 (2H, br s, tetrahydropyridinyl CH2), 2.64 (2H, br s, tetrahydropyridinyl CH2), 3.08 (2H, br s, ~VO 94120459 ~ PCT/GB94100384 tetrahydropyridinyl CH2), 3.74 (2H, s, NC~2Ar), 5.98 (lH, br s, tetrahydropyridinyl 5-CH), 6.70 (lH, d, J 16.1Hz, CH=CHAr), 6.94 (lH, d, J 16.1Hz, CH=C~Ar), 7.01-7.05 (lH, m, ArH), 7.23-7.32 (2H, m, ArH), 7.37-7.43 (2H, m, ArH), 7.72 (lH, d, J 6.7Hz, ArH), 8.03 (lH, d, J 7.7Hz, ArH), 8.19 (lH, br s, ArH), and 11.46 (lH, br s, NH); m/z (CI+, NH3) 350 (M+l)+.

(~)-3-(4-r2-(4-Chloropher~,yl)ether~yll-1.2.3.6-tetrahydropYridin- 1-YI )methvlpyrrolor2.3-blDyridine M.p. 214-217C (xylene); (Found: C, 71.34; H, 5.87; N, 11.60. C2lH2oClN3Ø2H2O requires C, 71.36; H, 5.82; N, 11.89~);
~H (DMSO-d6) 2.29 (2H, br s, tetrahyd~ o~ ;dinyl CH2), 2.61 (2H, t, J 5.7Hz, tetrahyd,ol,yl;dinyl CH2), 3.07 (2H, br s, tetrahy~vl,yl;dinyl CH2), 3.73 (2H, s, NCHAr), 5.91 (lH, br s, tetrahyd,v~yl;dinyl 5-CH), 6.44 (lH, d, J 16.3Hz, C~=CHAr), 6.90 (lH, d, J 16.3Hz, CH=C~IAr), 7.01-7.04 (lH, m, ArH), 7.34-7.38 (3H, m, ArH), 7.48 (2H, d, J 8.5Hz, ArH), 8.02 (lH, d, J
7.8Hz, ArH), 8.15-8.19 (lH, m, ArH), and 11.45 (lH, bs, NH);
m/z CI+, NH3) 350 (M+l)+.
~X~MPLE 17 (~)-3-(4-r2-(Thien-2-yl)ethenyll-1.2.3.6-tetrahvdlv~ din-l-yl)methvlpyrrolo~2.3-blpyridine M.p. 202-204C (MeOH); (Found: C, 70.59; H, 5.94; N, 12.20. ClgHlgN3S requires C, 70.99; H, 5.96; N, 13.07~ H
(DMSO-d6) 2.26 (2H, br s, tetrahydropyridinyl CH2), 2.60 (2H, t, J 5.7Hz, tetrahydropyridinyl CH2), 3.05 (2H, br s, WO 94/2W59 , ~ PCT/GB94/00384 tetrahydropyridinyl CH2), 3.72 (2H, s, NCH2Ar), 5.85 (lH, br s, tetrahydropyridinyl 5-H), 6.58 (lH, d, J 16.1Hz, CH=CHAr), 6.64 (lH, d, J 16.1Hz, CH=C~Ar), 6.98-7.07 (3H, m, ArH), 7.37 (2H, br B, ArH), 8.02 (lH, d, J 6.4Hz, ArH), 8.19 (lH, d, J 3.1Hz, ArH), and 11.42 (lH, br s, NH).

~XAl~IPT.F~ 18 3-(4-r2-(Fl~r~n-2-yl)ethyll-1.2.3.6-tetr~lydropyridin-1-yl~lnetb,yl-lH-Dyrrolor2.3-blpyridine ~teD 1: 1-(Pyrirlin-4-yl)-2-(fur~n-2-vl)ethene A solution of 4-methylpyridine (15g, 0.16mol) in acetic anhydride (lOOml) was treated with 2-furaldehyde (15.6g, 0.16mol) and heated at reflux for 16 hr. The solvent was eva~o~ated to give a black oil which was treated with water (30ml) and stirred for 30 mins at room t~mrerature. Ethyl acetate (150ml) and saturated sodi-lm carbonate (lOOml) were then added and the stirring continued for 30 mins. The supernatant was decanted to leave a black oily residue which was retained (A). From the decanted solvents the organic phase was separated, dried (Na2SO4) and evaporated to give a black oil (B). The oily residue (A) was dissolved in dichloromethane (150ml), washed with saturated sodium carbonate solution (lOOml), dried (Na2SO4) and evaporated to give a black oil which was combined with oil (B). The mixture was chromatographed on silica gel with a gradient of ethyl acetate in hexane (50% -100%) as eluant to afford the title compound as a brown solid (9.8g, 36~ H(DMSO-d6) 6.58-6.64 (lH, m, furanyl H), 6.66-6.72 (lH, m, furanyl H), 6.96 (lH, d, J 17.5Hz, ArCH=CHAr ), ~0 94/20459 ~? PCT/GB94/00384 ~s~lo 7.42 (lH, d, J 17.5Hz, ArCH=C~Ar ), 6.50-6.58 (2H, m, pyridinyl CH), 7.78-7.82 (lH, m, furanyl H), and 8.50-8.51 (2H, m, pyridinyl H).

- ~SteD 2: 1-(Pyridin-4-vl)-2-(f~r~n-2-yl)eth~ne A solution of 1-(pyridin-4-yl)-2-(furan-2-yl)ethene (8g, 46.8mmol) in methanol (200ml) was treated with ammonium formate (14.7g, 234.0mmol). 10% Palladium on charcoal catalyst (400mg, 5% (w/w)) was added and the mixture was stirred at reflux for five hours. The catalyst was filtered off and the solvent evaporated. The residue was partitioned between dichloromethane and water. The organic layer was separated, dried (MgSO4) and evaporated to give a beige oil. This material was chromatographed on silica gel with a gradient of ethyl acetate in heY~ne (50%-100%) as eluant to afford the title compound as a colourless oil (2.5g, 31%); oH(DMSO-d6) 2.94-3.06 (4H, m, 2 x CH2), 6.06-6.12 (lH, m, furanyl H), 6.32-6.38 (lH, m, furanyl H), 7.20-7.28 (2H, m, pyridinyl H), 7.50-7.56 (lH, m, furanyl H), and 8.40-8.50 (2H, m, pyridinyl H).

~ Step 3: 1-Benzyl-4-(2-rfuran-2-vllethvl)-1.2.3.6-tetrahy~l. o~y~ ne A solution of 1-(pyridin-4-yl)-2-(furan-2-yl)ethane (2g, 11.6mmol) in anhydrous dimethylformamide (5ml) was treated with benzyl bromide (1.5ml, 12.7mmol) and the reaction stirred at room temperature for one hour. The reaction was diluted with ethanol (50ml), treated with sodium borohydride (0.55g, 14.5mmol) and heated at reflux for one hour. The solvent was evaporated and the residue partitioned between ethyl acetate WO 94/20459 6~ PCT/GB94/00384 and water. The organic was separated, dried (Na2SO4) and evaporated to give crude product as a yellow oil. This material was triturated with diethyl ether to afford the title compound (2.3g, 68%) as a colourless solid; OH (DMSO-d6) 1.92-2.10 (2H, m, tetrahydropyridinyl CH2), 2.14-2.30 (2H, m, CH2), 2.36-2.50 (2H, m, CH2), 2.60-2.82 (2H, m, tetrahydropyridinyl CH2), 2.84-2.90 (2H, m, tetrahyLo~yl;dinyl CH2), 3.50 (2H, br s, PhC~2N), 5.32-5.44 (lH, m, tetrahydropyridinyl 5-H), 6.02-6.10 (lH, m, furanyl H), 6.30-6.36 (lH, m, furanyl H),7.16-7.36 (5H, m, ArH), and 7.44-7.52 (lH, m, furanyl H); m/z (CI~, NH3) 268 (M+1)+.

~tep4: 4-(2-rFllr~n-2-yllethyl)-1.2.3.5-tetr~lYrlropyri-line A cooled (0C) solution of 1-benzyl-4-(2-[furan-2-yl]ethyl)-1,2,3,6-tetrahydropyridine (1.8g, 6.8mmol) in anhydrous dichloromet~ne (20ml) was treated with 1-chloroethylchlolofol~late (0.95ml, 8.8mmol) dropwi6e. The miYtllre was stirred for 1 hr at 0C. The solvent was evaporated and the residue dissolved in methanol (60ml). This solution was heated at reflux for one hour whereupon the solvent was evaporated. The residue was partitioned between dichloromethane and saturated aqueous potassium carbonate solution. The organic phase was separated, dried (Na2SO4) and evaporated to give the title compound (867mg, 72%) as a colourless oil; ~H (DMSO-d6) 1.84-1.96 (2H, m, tetrahydlol,yl;dinyl CH2), 2.16-2.30 (2H, m, CH2), 2.64-2.80 (4H, m, tetrahydropyridinyl CH2 and CH2), 3.06-3.10 (2H, m, tetrahydropyridinyl CH2), 5.40-5.46 (lH, m, tetrahydropyridinyl 5-H), 6.06-6.12 (lH, m, furanyl H), 6.32-6.38 (lH, m, furanyl H), and 7.48-7.56 (lH, m, furanyl H).

WO 94/20459 ~ ^6' PCT/GB94/00384 Step 5: 3-(4-r2-(Fl-r~n-2-vl)ethyll-1.2.3.6-tetr~hydropyri-lin-l-yl)met,llyl-lH-pYrrolor2.3-blpyrir~ine A solution of 4-(2-[furan-2-yl]ethyl)-1,2,3,6-tetrahydropyridine (506mg, 2.86mmol) and 3-dimethyl~minomethyl-1H-pyrrolo[2,3-b]pyridine (500mg, 2.86mmol) in toluene (10ml) was stirred at reflux for 10 hours.
The solvent was evaporated and the residue chromatographed with 3% methanol in dichloromethane as eluant to afford the title compound (200mg, 23%) as a colourless solid, m.p. 105C;
(Found: C, 73.84; H, 6.72; N, 13.31. ClgH2lN3O requires C, 74.24;
H, 6.89; N, 13.67); OH (DMSO-d6) 2.00-2.06 (2H, m, tetrahydropyridinyl CH2), 2.22 (2H, t, J 7.7Hz, CH2), 2.48-2.54 (2H, m, CH2), 2.68 (2H, t, J 7.3Hz, tetrahy-llo~yl;dinyl CH2), 2.84-2.89 (2H, m, tetrahydlo~ylidinyl CH2), 3.66 (2H, s, NCH2Ar), 5.34-5.38 (lH, m, tetrahydropyridinyl 5-H), 6.06 (lH, d, J 2.9Hz, furanyl 3-H), 6.31 (lH, dd, J 3.0, 1.9Hz, furanyl 4-H), 7.02 (lH, dd, J 7.8, 4.6Hz, 5-H), 7.32 (lH, d, J 2.3Hz, furanyl 5-H), 7.46 (lH, d, J 3.0Hz, 2-H), 7.99 (lH, m, dd, J 7.8, 4.1Hz, 4-H), 8.18 (lH, dd, J 4.6, 1.4Hz, 6-H), and 11.38 (lH, br s, NH);
m/z (CI+, NH3) 308 (M+1)+.
T;~Al~PT,F: 19 3-(4-r2-(TetrahYdrofilr~n-2-yl )ethyll- 1.2.3.6-tetrahYdrol~vridin- 1 -yl )methvl- lH-pyrrolor2.3-blpvridine Step 1: 4-(2-rTetrahydrofuran-2-yllethyl)pyridine A solution of 1-(pyridin-4-yl)-2-(furan-2-yl)ethene (15.0g, 87.7mmol) rExample 18, Step 1] in methanol (300ml) was treated with ammonium formate (27.6g,438.5mmol) and lO"~o WO 94/204S9 ~ 6~ PCT/GB94/00384 p~ lium on charcoal catalyst (1.5g, 10% (w/w)). The mixture was stirred at reflux for 3 hours. The catalyst was removed by filtration and the solvent was evaporated in vacuo. The residue was partitioned between ~i~hloromethane and water. The 5 organic phase was separated, dried (MgSO4) and evaporated in vacuo. The residue was chrom~t~Fraphed with 1:1 h~Y~n~/ethyl ~ret~te as eluant to afford the tit~e compound as a colourless oil (3.0g, 19%); 'OH tDMSO-d6) 1.35-1.50 (lH, m, tetrahydrofuranyl H), 1.70-2.00 (5H, m, CH2 and 3 x tetrahydrofuranyl H), 2.54-2.76 (2H, m, CH2), 3.54-3.82 (3H, m, tetrahydrofuranyl H), 7.22 (2H, d, J 7.1Hz, ArH), and 8.46 (2H, d J 7.0Hz, ArH); m/z (CI+, NH3) 178 (M+1)+.

~;te~ ~: 1-Renzyl-4-(2-rtetr~lyrlrofilr~n-2-vllet~ 3.6-15 tetr~hv~ vrl;lline A solution of 4-(2-[tetrahydrofuran-2-yl]ethyl)pyridine (3.0g, 16.9mmol) in anhydrous dimethylformamide (51) was treated with benzyl bromide (2.2ml, 18.6mmol) and the ~ e was stirred at room t~mperature for one hour. The reaction was diluted with absolute ethanol (lOOml), treated with sodium borohydride (0.8g, 21.2mmol) and stirred at reflux for one hour.
The solvent was evaporated in vacuo and the residue partitioned between diethyl ether and water. The organic layer was separated, dried (Na2SO4) and evaporated in vacuo. The residue was chromatographed with 3% methanol in dichloromethane as eluant to afford the title compound (3.75g, 82%) as a colourless oil; ~H (DMSO-d6) 1.30-2.08 (8H, m,4 x CH2), 2.45-2.52 (2H, m, tetrahydropyridinyl CH2), 2.52-2.56 (2H, m, CH2), 2.60-2.66 (2H, m, tetrahydropyridinyl CH2), 3.50 (2H, s, PhCH2N), 3.52-3.80 (3H, m, tetrahydrofuranyl CH2 and CH), 5.50-5.55 (lH, m, WO 94/20459 ?~, PCT/GB94/00384 tetrahydropyridinyl 5-H), and 7.20-7.34 (5H, m, ArH); m/z (CI+, NH3) 272 (M+1)~.

~teD 3: 3-(4-r2-tTetr~hY~rofilr~n-2-yl)ethvll-1.2.3.6-tetr~hYr~roDyrirlin-l-yl)methYl-t~-pyrrolor2;3-blDvri~ine A solution of the foregoing compound (3.75g, 13.8mmol) in anhydrous dichloromethane (150ml) was cooled to 0C and treated with a solution of 1-chloroethylchloroformate (1.94ml, 18.0mmol)inanhydrousdichloromethane(50ml). Afterstirring at room tempel atul e for one hour, the solvent was evaporated a~d the residue redissolved in methanol (200ml). This solution was stirred at reflux for two hours. The solvent was evaporated and the residue partitioned between dichloromethane and saturated aqueous potassium carbonate solution. The organic phase was separated, dried (MgSO4) and evaporated to afford the crude product (2.49g, 99.6%) as a gummy solid.

A solution ofthe crude tetrahy~l,o~y~;dine (517mg, 2.86mmol) and 3-dimethylaminomethyl-lH-pyrrolo[2,3-b]pyridine (500mg, 2.86mmol) in toluene (lOml) was stirred at reflux for 10 hours. The solvent was evaporated and the residue chromatographed with 3% methanol in dichloromethane as eluant to afford the title compound (175mg, 20%) as a colourless 26 solid, m.p. 70-72C; (Found: C, 72.29; H, 7.86; N, 13.97.
ClgH2sN30Ø25H20 requires C, 72.23; H, 8.13; N, 13.30); ~H
(DMSO-d6) 1.30-1.60 (3H, m, 3 x tetrahydrofuranyl H), 1.70-2.08 (7H, m, 1 x tetrahydrofuranyl H, CH2CH2 and 1 x tetrahydropyridinyl CH2), 2.50 (2H, m, tetrahydropyridinyl CH2 under DMSO peak), 2.86 (2H, br s, tetrahydropyridinyl CH2), 3.50-3.76 (5H, m, ArCH2N and 3 x tetrahydrofuranyl H), 5.30-WO 94/20459 3,~ PCT/GB94/00384 5.36 (lH, m, tetrahydropyridinyl 5-H), 7.02 (lH, dd, J 7.8, 4.6Hz, 5-H), 7.33 (lH, d, J 2.2Hz, 2-H), 7.98 (lH, dd, J 7.8, 1.1Hz, 4-H), 8.18 (lH, dd, J 4.6, 1.1Hz, 6-H), and 11.42 (lH, m, NH). m/z (CI+, NH3) 312 (M+1)~.

F.~Al~PT~ 0 3-(4-r2-(5-Methylfuran-2-vl)ethyll-1.2.3.6-tetr~hy~o~JYl;llin-l-yl)rnethyl-lH-pyrrolor2.3-blpyri~ine 1-Benzyl-4-(2-[5-methylfuran-2-yl]ethyl)-1,2,3,6-tetrahy.L ~ ldine was prepared in the same manner as 1-benzyl-4-[2-furan-2-yl]ethyl)- 1,2,3,6-tetrahydropyridine (F'Y~mple 18).
A solution of 1-benzyl-4-(2-[5-methylfuran-2-yl]ethyl)-1,2,3,6-tetrahy~..p~l,dine (1.5g, 5.34mmol) in anhydrous dichloromethane (lOOml) was cooled to 0C and treated with a solution of 1-chloroethylchloroformate (0.75ml, 6.94mmol) in anhydrous dichloromethane (60ml). After stining at room temperature for one hour, the solvent was evaporated and the residue redissolved in methanol (160ml). This solution was stirred at reflux for two hours. The solvent was evaporated and the residue partitioned between dichloromethane and saturated aqueous potassium carbonate solution. The organic phase was separated, dried (MgSO4) and evaporated to afford the crude product (1.Og, 99%) as a brown oil.

A solution of the crude tetrahydropyridine (500mg, 2.6mmol) and 3-dimethyl?.minnmethyl-1H-pyrrolo[2,3-b~pyridine (416mg, 2.38mmol) in toluene (20rnl) was stirred at reflux for 8 ~S~o hours. The solvent was evaporated and the residue chromatographed with 3% methanol in dichloromethane as eluant to afford the title compound (160mg,21%) as a colourless solid, m.p. 118-119C; (Found: C, 74.04; H, 7.01; N, 12.55.
C2oH2~N30Ø175H20 requires C, 74.01; H, 7.25; N, 12.95); ~H
(DMSO-d6) 1.95-2.06 (2H, m, tetrahydropyridinyl CH2), 2.14-2.24 (5H, m, CH3 and C~2CH2), 2.48-2.54 (2H, m, CH2C~2), 2.61 (2H, t, J 7.4Hz, tetrahydropyridinyl CH2), 2.84-2.93 (2H, m, tetrahydropyridinyl CH2), 3.66 (2H, s, NCH2Ar), 5.35-5.40 (lH, m, tetrahydropyridinyl 5-H), 5.87-5.95 (2H, m, furanyl H), 7.01 (lH, dd, J 7.9, 4.8Hz, 5H), 7.33 (lH, d, J 2.3Hz, 2-H), 7.99 (lH, dd, J 7.8, 1.2Hz, 4-H), 8.17 (lH, dd, J 4.6, 1.4Hz, 6-H), and 11.41 (lH, br s, NH); m/z (CI+, NH3) 322 (M+1)+.

~Al\~PT,F~ 21 3-(4-F:t.~v]-1.2.3,6-tetr~l~yd~o~yl;din-1-yl)methvl-lH-pyrrolor2.3-blDvri~ine ~;te~ enzyl-4-ethvl-1.2.3.6-tetrahydropyri~ine A solution of 4-ethylpyridine (3.0g, 28mmol) in anhydrous dimethylformamide (lOml) was treated with benzyl bromide (3.7ml, 31mmol) and the mixture was stirred at room 25 temperature for two hours. The reaction mixture was diluted with absolute ethanol (60ml), treated with sodium borohydride (1.3g, 35mmol) and stirred at reflux for one hour. The solvent was evaporated in vacuo and the residue partitioned between dichloromethane and water. The organic phase was separated, 30 dried (MgSO4) and evaporated in vacuo. The residue was chromatographed with 1:1 hexane/ethyl acetate as eluant to give r the title compound (1.92g, 34% over two steps) as a colourless oil;
~H (CDCl3) 1.00 (3H, t, J 7.5Hz, CH2C~3), 1.94-2.12 (4H, m, CH2CH3 and tetrahydropyridinyl CH2), 2.55 (2H, t, J 6.3Hz, tetrahydropyridinyl CH2), 2.90-3.00 (2H, m, tetrahydlvl~y~idinyl CH2), 3.58 (2H, s, PhCH2N), 5.32-5.40 (lH, m, tetrahydropyridinyl 5-H), and 7.20-7.40 (5H, m, ArH); m/z (CI~, NH3) 202 (M+1)+.

~;te~ ~: 3-(4-F~thvl-1.2.3.6-tetr~ydropyrillin-1-yl)-met~yl-lH-~vrrolor~.3-bl~vri(line A solution of 1-benzyl-4-ethyl-1,2,3,6-tetrahydropyridine (1.92g, 9.6mmol) in anhydrous dichloromethane (50ml) was cooled to 0C and treated with a solution of 1-chloroethylchloroformate (1.34ml, 12.4mmol) in anhydrous dichloromethane (10ml). After stirnng at room temperature for one hour, the solvent was evaporated and the residue redissolved in methanol (50ml). This solution was heated at reflux for one hour. The solvent was evaporated and the residue partitioned between dichloromethane and saturated aqueous potassium carbonate solution. The organic phase was separated, dried (MgSO4) and evaporated in uacuo to afford the crude product (320mg, 30%) as a colourless oil. A solution of the crude tetrahydropyridine (320mg, 2.9mmol) and 3-dimethyl~minomethyl-lH-pyrrolo[2,3-b]pyridine (504mg, 2.9mmol) in toluene (lOml) was stirred at reflux for 16 hours.
The solvent was evaporated and the residue chromatographed with 3% methanol in dichloromethane as eluant to af~ord the tit~e compound (300mg, 43%) as a colourless solid, m.p. 88-90C;
(Found: C, 74.03; H, 7.94; N, 16.97. Cl5HlgN~Ø125H20 requires C, 73.96; H, 7.97; N, 17.25%); ~H (DMSO-d6) 0.99 (3H, t, J 7.5Hz, ~g~/~

CH2C~3), 1.97 (2H, q, J 7.5Hz, C~I2CH3), 2.06-2.12 (2H, m, tetrahydropyridinyl CH2), 2.61 (2H, t, J 5.8Hz, tetrahyd~o~yl;dinyl CH2), 3.02-3.08 (2H, m, tetrahydropyridinyl CH2), 3.78 (2H, s, NCH2Ar), 5.34-5.40 (lH, m, tetrahydru~yl;dinyl 5-H), 7.08 (lH, dd, J 7.9,4.8Hz, 5-H), 7.29 (lH, m, 2-H), 8.06-8.04 (lH, m, 4-H), 8.28-8.32 (lH, m, 6-H), 9.28 (lH, br 8, NH). m/z (CI~, NH3) 242 (M+1)+.

F~XAl\~PT,F~ ~2 Re~oic z~cirl l-(lH)~yrrolor2.3-bl~vridin-3-vl-methyl) 1 ~3.6-tetr~hv~l . o~.yl ;rlin-4-vlInet~yl ester ~;te~ er~7~yl-4-hv(l.c,~yl..etllvl-1~.3 6-tetr~.l. o.,v~ ;rline A solution of 4-hy~l~u~y~ethylpyridine (20g, 0.183mol) in anhydrous dimethylforrn~mi-le (70ml) was treated with benzyl bromide (24ml, 0.202mol) and the mixture was stirred at 100C
fûr two hours. The reaction was cooled to room temperature and diluted with absolute ethanol (250ml). Sodium borohydride (8.7g, 0.229mol) was added portionwise and the mixture stirred at reflux for 3 hours. The solvent was evaporated in vacuo and the residue partitioned between dichloromethane and water.
The organic phase was separated, dried (MgSO4) and evaporated in uacuo. The residue was chromatographed with 1:1 hexane/ethyl acetate as eluant to the title compound (13g, 355'o) as a lemon yellow solid; OH (CDCl3) 2.12-2.20 (2H, m, tetrahydropyridinyl CH2), 2.60 (2H, t, J 7.5Hz, tetrahydropyridinyl CH2), 2.96-3.04 (2H, m, tetrahydropyridyl CH2), 3.60 (2H, s, PhCH2N), 4.00-4.04 (2H, m, CH2OH),5.60-2~

6.66 (lH, m, tetrahydropyridinyl 5-H), and 7.20-7.40 (5H, m, ArH). m/z (CI~, NH3) 204 (M+1)~.

~te~ 2: P~en70ic ~citl 1-be~7~yl-1.2.3.6-tetr~l~Lo~ ;tlin-4-ylmethvl ester A cooled (ice-bath) solution of the foregoing compound (lg, 4.9mmol) in dichloromethane (30ml) was treated with sodit~m hydroxide solution (2M, 30ml) and a solution of benzoylchloride (0.58ml,4.9mmol) in dichloromethane (lOml).
The mixture was stirred at 0C for 2 hours. The organic layer was separated, dried (MgSO4) and evaporated in vacuo to afford the ~itle compound (1.37g, 91%) as a colourless oil;. ijH (DMSO-d6) 2.12-2.20 (2H, m, tetrahydropyridinyl CH2), 2.55 (2H, t, J
7.5Hz, tetrahy~Lv~yl;dinyl CH2), 2.95-3.05 (2H, m, tetrahydropyridinyl CH2), 3.55 (2H, s, PhCE2N), 4.72 (2H, s, CH20), 5.75-5.82 (lH, m, tetrahydropyridinyl 5-H), 7.22-7.38 (5H, m, ArH), 7.48-7.57 (2H, m, ArH), 7.64-7.70 (lH, m, ArH), and 7.96-8.04 (2H, m, ArH); m/z (CI~, NH3) 308 (M+1)~.
~tep 3: Re~ojc ~ci-l 1-(lH-pyrrolor2.3-blDvrir7in-3-ylmethvl)-1.~.3.6-tetr~llydropvri~in-4-ylmethvl ester A solution of benzoic acid 1-benzyl- 1,2,3,6-tetrahydfo~yl;din-4-ylmethyl ester (1.35g, 4.4rmmol) in anhydrous dichloromethane (50ml) was cooled to 0C and treated with a solution of l-chloroethyl-chloroformate (0.62ml, 5.7mmol) in anhydrous dichloromethane (lOml). After stirring at 0C for 1.5 hours, the solvent was evaporated and the residue redissolved in methanol (50ml). This solution was stirred at refllLlc for two hours. The solvent was evaporated and the ~s6q~?~

residue partitioned between ethyl acetate and saturated aqueous potassium carbonate solution. The organic phase was separated, dried (MgSO4) and evaporated ~n vacuo to afford the crude product (520mg, 58% over two steps) as a colourless oil. A
5 solution of the crude tetrahydropyridine (520mg, 2.5mmol) and 3-dimethyl~minomethyl-lH-pyrrolo[2,3-b]pyridine (520mg, 2.5mmol) in toluene (20ml) was stirred at reflux for 9 hours. The solvent was evaporated and the residue chromatographed with 5~ methanol in dichloromethane as eluant to af~ord the title compound (480mg, 55%) as a colourless solid, m.p. 126C;
(Found: C, 72.42; H, 6.08; N, 12.15. C2lH2lN3O2 requires C, 72.60; H, 6.09; N, 12.10%); ~OH (CDCl3) 2.20-2.30 (2H, m, tetrahydropyridinyl CH2), 2.68 (2H, t, J 5.7Hz, tetrahydropyridinyl CH2), 3.05-3.10 (2H, m, tetrahydropyridinyl CH2), 3.80 (2H, s, NC~2Ar), 5.86-5.94 (lH, m, tetrahydropyridinyl 5-H), 4.74 (2H, s, CH2O), 7.07 (lH, dd, J
7.8, 4.7Hz, 5-H), 7.20-7.30 (lH, m, ArH), 7.38-7.45 (2H, m, ArH), 7.50-7.60 (lH, m, ArH), 8.00-8.10 (3H, m, ArH), 8.30 (lH, dd, J
4.7, 1.5Hz, 6-H), and 9.33 (lH, s, NH); m/z (CI+, NH3) 348 (M+1)~.

MPT ~ 23 3-(4-r2-(3-MethoxyDhenvl)ethenvll-1.2.3.6-tetr~?~y.llo~ Ylldin-l-yl)methvl-lH-~yrrolor2.3-blpyridine M.p. 186-188C (PhMe); (Found: C, 76.52; H, 6.93; N, 11.55. C22H23N3O requires C, 76.49; H, 6.71; N, 12.16%); OH
(CDCl3) 2.44 (2H, br s, tetrahydrol,yl;dinyl CH2), 2.77 (2H, br s, tetrahydropyridinyl CH2), 3.23 (2H, br s, tetrahydropyridinyl CH2), 3.81 (3H, s, OCH3), 3.86 (2H, s, ArCH.~N), 5.81 (lH, br s, 2~6~ ~

tetrahydropyridinyl 5-H), 6.41 (lH, d, J 16.0Hz, ArCH=CHR), 6.75-6.79 (lH, m,4'-H), 6.77 (lH, d, J 16.0Hz, ArCH=CHR), 6.93 (lH, br s, 2'-H), 6.99 (lH, d, J 7.7Hz, 6'-H), 7.08 (lH, dd, J 7.9, 4.8Hz, 5-H), 7.22 (lH, t, J 7.9Hz, 5'-H), 7.33 (lH, br s, 2-H), 8.09 (lH, d, J 7.9Hz, 4-H), 8.31 (lH, dd, J 4.8, 1.6Hz, 6-H), and 9.15 (lH, br s, NH); m/z (CI+, NH3) 346 (M+l)+.

~X~MPT ~ 24 3-(4-PhenoxyTnethvl-1.~.3.6-tetr~Y~roDyriflin-l-yl)methYl-l~I-pyrrolor2.3-bl~Yri~ine M.p. 161-163C (MeOH); (Found: C, 75.05; H, 6.61; N, 12.91. C20H2lN3O requires C, 75.21; H, 6.63; N, 13.16%); ~H
(CDCl3) 2.25 (2H, br s, tetrahydropyridinyl CH2), 2.69 (2H, t, J
5.7Hz, tetrahy~ ;dinyl CHa), 3.09(2H, br 8, tetrahy~ "dinyl CH2), 3.81 (2H, s, ArC~2N), 4.40 (2H, s, ArC~20), 5.77 (lH, br ~, C~l=CR), 6.89-6.95 (3H, m, ArH), 7.08 (lH, dd, J 7.8, 4.7Hz,5-H), 7.24-7.29 (3H, m, ArH), 8.07 (lH, dd, J 7.9, 1.5Hz, 4-H),8.31 (lH, dd, J 4.8, 1.6Hz, 6-H), and 9.69 (lH, br s, NH); m/z (CI+, NH3) 320 (M+l)+.

~)-3-(4-r2-(5-Methylfur~n-2-vl )ethenvll- 1.2.3.6-tetrahydrop,Yridin-l-yl)methyl-lH-p,Yrrolor2.3-blp,Yridine Ste~ 1: (E)-l-tert-ButyloxYcarbonyl-3-(4-r2-(5-methvlfuran-2-vl )ethenyl l- 1.2.3.6-tetrahYdropvridin- 1 -vl)methvlpYrrolo~2.3-blDYridine WO 94/20459 ,~ PCT/GB94/00384 ls~o A solution of 1-(5-methylfuran-2-yl)-2-(pyridin-4-yl)ethene (315mg, 1.7mmol) in anhydrous dimethylformamide (5ml) was treated with a solution of(E)-1-tert-butylo,~yc~bonyl-3-chloromethylpyrrolo[2,3-b]pyridine (500mg, 1.9mmol) [prepared using the method of Sanchez-Obregon et al., Can. J. Chem., 1992, 70, 1531-1536] in anhydrous dimethylform~mirle (5ml).
The mixture was stirred at 70C for 16 hours. The reaction was diluted with ethanol (50ml) and treated with sodium borohydride (81mg, 2.13mmol). The mixture was stirred at room temperature for a further two hours whereupon the solvent was evaporated in vacuo and the residue partitioned between ethyl acetate and saturated brine solution. The organic layer was separated, dried (Na2SO4) and evaporated in vacuo. The residue was chromatographed on silica gel with 50% hexane/ethyl acetate as eluant to afford the tit~e compound as an orange oil (160mg, 22~ H (CDCl3) 1.60 (9H, s, C(CH3)3), 2.20-2.33 (5H, m, tetrahydropyridinyl CH2 and ArCH3), 2.58-2.66 (2H, m, tetrahydfol,yl;dinyl CH2), 3.06-3.16 (2H, m, tetrahydropyridinyl CH2), 3.67 (2H, 2, NC~2Ar), 5.67-5.75 (lH, m, tetrahydropyridinyl 5-H), 5.87-5.91 (lH, m, furan 4-H), 6.04-6.07 (lH, m, furan 3-H), 6.13 (lH, d, J 16.2Hz, CH=C~Ar), 6.58 (lH, d, J 16.1Hz, C~=CHAr), 7.08-7.14 (lH, m, 5-H), 7.48-7.52 (lH, m, 2-H), 7.96-8.04 (lH, m, 4-H), and 8.40-8.46 (lH, m, 6-H); m/z (CI~, NH3) 420 (M+1)~.
~tep 2: (E)-3-(4-r2-(5-methylfur~n-2-vl)ethenyll-1.2.3.6-tetrahydl o~v, ;din- l-yl )methyl- lH-nyrrolor2.3-blpvridine A solution of (E)-1-tert-butyloxycarbonyl-3-(4-[2-(5-methylfuran-2-yl)ethenyl]-1,2,3,6-tetrahydropyridin-1-yl)methylpyrrolo[2,3-b]pyridine (160mg, 0.38mmol) in anhydrous WO 94/20459 ~ PCT/GB94/00384 2~56~ L~

dichloromethane (5ml) was treated with trifluoroacetic acid (500ml, 6.5mmol) and stirred at room temperature for two hours.
.~mmonium hydroxide solution (5ml) was added and the whole miYtllre evaporated in vacuo. The residue was azeotroped with 5 toluene. The crude material was-chromatographed on silica gel with 5% methanol in dichlorometll~ne as eluant to afford the title compound as a pale lemon solid (70mg,57%), m.p. 180C
(dec.); (Found: C, 71.47; H, 6.46; N, 12.01. C20H2lN3O.H2O
requires C,71.19; H, 6.87; N, 12.42%); ~H (DMSO-d6) 2.15-2.30 (5H, m, tetrahydropyridinyl CH2 and ArCH3), 2.59 (2H, t, J
5.5Hz, tetrahy~Lo~y~;dinyl CH2), 3.02-3.10 (2H, m, tetrahy~Lol,ylldinyl CH2), 3.71 (2H, s, NCH2Ar), 5.78-5.86 (lH, m, tetrahydropyridinyl 5-H), 6.05-6.10 (lH, m, furan 4-H), 6.16-6.30 (2H, m, CH=CHAr and furan 3-H), 6.55 (lH, d, J 16.1Hz, C~=CHAr), 7.02 (lH, dd, J 7.8, 4.8Hz, 5-H),7.34-7.38 (lH, m, 2-H), 8.01 (lH, d, J 7.8Hz, 4-H), 8.18 (lH, d, J 4.6Hz, 6-H), and 11.45 (lH, s, NH); m/z (CI~, NH3) 320 (M+1)+.

~XAl~PT.~: 26 6-Pher~yl-2-(1H-pyrrolor2.3-blpyridin-3-vlmethyl)-1.~!.3.4-tetrahvdroisoquinoline A mixture of 6-phenyl-1,2,3,4-tetrahydroisoq~inoline 25 (prepared by the method of L N Pridgen, J. Heterocyclic Chem.
1980, 17, 1289) (0.5g, 2.38mmol) and 3-dimethyl~minomethyl-lH-pyrrolo[2,3-b]pyridine (0.4g, 2.28mmol) in toluene (5ml) was heated at reflux under nitrogen for 18h. The mixture was allowed to cool and the crystallised product collected.
30 Recrystallisation from ethyl acetate afforded the title compound (0.13g, 17'7o), m.p. 211-213C; (Found: C, 80.15; H, 6.30; N, 12.32. C23H2lN3Ø3H2O requires C, 80.11; H, 6.31; N, 12.18%3;
~iH (DMSO-d6) 2.73 (2H, br s, CH2CEI2Ph), 2.87 (2H, br s, NCH2CH2),3.61 (2H, s, ArC~2N), 3.83 (2H, s, NC~2Ph), 7.02 (lH, dd, J 7.8, 4.6Hz, 5-H), 7.18 (lH, d, J 3.2Hz, 2-H), 7.30-7.45 (6H, m, ArH), 7.60 (2H, d, J 7.6Hz, ArH), 8.05 (lH, d, J 7.6Hz,4-H), 8.20 (lH, dd, J 6.1, 1.4Hz, 6-H), and 11.48 (lH, br s, NH);
m/z (CI+, NH3) 340 (M+l)+.

~XAl\~P!.F~ 27 6-Methoxy-2-( lH-pvrrolor2.3-bll~vridin-3-vlmethyl)-1~.3.4-tetr~ll,y lroiso~l~inoline A mixture of 6-methoxy-1,2,3,4-tetrahydroisoql-inoline (prepared by the method of Helfer, Helv. Chim. Acta, 1924, 7, 945) (0.55g, 3.36mmol) and 3-dimethyl;~minomethyl-lH-pyrrolo[2,3-b]pyridine (0.59g, 3.36~nmol) in toluene (3ml) was heated at reflux under nitrogen for 18h. The mixture was allowed to cool and the cryst~llised product collected.
Recryst~ tion from toluene af~orded the title compound (0.31g, 32%), m.p. 144-146C; (Found: C, 73.04; H, 6.43; N, 14.10. Cl8HlgN3OØ1H2O requires C, 73.24; H, 6.55; N, 14.23%);
~H (DMSO-d6) 2.67 (2H, br s, CH2), 2.76 (2H, t, J 5.4Hz, CH2), 3.49 (2H, s, CH2), 3.69 (3H, s, OCH3), 3.78 (2H, s, CH2), 6.65 (2H, m, ArH), 6.89 (lH, d, 9Hz, ArH), 7.01 (lH, dd, J 7.9, 4.7Hz, 5-H), 7.40 (lH, d, J 2.2Hz, ArH), 8.03 (lH, dd, J 7.7, 1.3Hz, 4-H), 8.19 (lH, dd, J 4.6, 1.4Hz, 6-H), and 11.47 (lH, br s, NH); rn/z (CI+, NH3) 294 (M+l)+.

~64~

F~XAl\~PT,~i~ 28 7-Phenvl-2-(lH-~yrrolor2.3-blpYridin-3-vlmethyl)-1.2.3.4-tetrahy~lroisoauinoline ~te~ 1: 7-Phe~vliso~inoline To a slurry of 7-(trifluoromethanesulfonyloxy)isoquinoline (prepared by the method of D.F. Ortwine et al., J. Med Chem., 1992, 35, 1345) (2.1g, 7.5mmol) in toluene (20ml) was added phenyl boronic acid (1.21g, 10mmol) and a 2M solution of sodium carbonate (16ml). The reaction vessel was filled with nitrogen, tetrakis(triphenylphosphine)palladium(0) (0.25g, 0 ~mmol) was added and the reaction ~ e was heated at 90C for 18h. The reaction mixture was diluted with ethyl acetate (50ml) and washed with sodium carbonate solution (50ml). The aqueous solution was extracted with ethyl acetate (2 x 50ml). The ethyl acetate extracts were combined, dried over magnesium sulphate, filtered and evaporated under reduced pressure to give an oil.
The oil was purified by flash chromatography using hexane/ethyl acetate (1:1) as eluant to give the title compound (1.27g, 83%); OH
(DMSO-d6) 7.41-7.88 (6H, m, ArH and isoquinolinyl H), 7.95 (lH, d, J 6.2Hz, isoquinolinyl H), 8.14 (lH, dd, J 8.5, 1.75Hz, isoqllinolinyl H), 8.44 (lH, t, J 0.85Hz, isoquinolinyl H), 8.52 (lH, d, 5.75Hz, 3-H), and 9.31 (lH, s, 1-H); m/z (CI+, NH3) 206 (M+1)+.

Step 2: 7-Phenvl-1.2.3.4-tetr~llydroisoQuinoline To a solution of 7-phenylisoquinoline (1.25g, 6.1mmol) in methanol (50ml) was added conc HCl (2ml) and platinum oxide ~0 (lOOmg). The reaction mixture was hydrogenated at 50 psi until no further uptake of hydrogen was observed. The catalyst was filtered off, washed with methanol. The filtrate was evaporated under reduced pressure to give a solid. The solid was partitioned between ethyl acetate and sodium carbonate solution. The aqueous solution was extracted with ethyl acetate (2 x 100ml).
The ethyl acetate extracts were combined, washed with brine (2 x 100ml), dried over magnesium sulphate, filtered and evaporated under reduced pressure to give an oil, which crystallised on stF.ntlin~. The solid was a mixture of the tit~e compound and 7-phenyl-decahydroisoquinoline; Rf 0.66 (EtOAclMeOH/NH3 5:1:1).

~tep 3: 7-Pher~yl-2-(1H-pyrrolor2.3-blpyridin-3-ylmethyl)-1.~.3.4-tetr~ vtlroiso~llinoline The lmxLu,e obtained from the previous step (0.5g, 2.38mmol) and 3-dimethyl~minomethyl-lH-pyrrolo[2,3-b]pyridine (0.42g, 2.39mmol) in toluene (3ml) was heated at reflux under nitrogen for 24h. The mixture was allowed to cool and the crystalline product collected. The solid was purified by flash chromatography, eluting with dichloromethane/
methanoVarnmonia. The apropriate fractions were comhined to give a solid (0.54g). The solid was recrystallised from toluene, and purified by reverse phase HPLC on a ~100, 5~Lm C8 columm (250mm x 20mm id) using 40% acetonitrile, 60~o H20 (cont~ining 0.1% TFA) as eluant. The appropriate fraction was evaporated under reduced pressure to dryness. The residue was partitioned between dichloromethane/methanol (9:1) and sodium hydroxide solution. The organic phase was evaporated under reduced pressure to give a solid. The solid was recrystallised from wo 94/20459 ~G ~ PCT/GB94/00384 toluene to give the title compound (0.14g, 17%), m.p. 203-205C;
(Found: C, 79.92; H, 6.02; N, 12.10. C23H2lN3Ø35H2O requires C, 79.90; H, 6.33; N, 12.15%); ~H (DMSO-d6) 2.72 (2H, t, J 5.4Hz, CH2), 2.82 (2H, t, J 5.4Hz, CH2), 3.63 (2H, s, CH2), 3.82 (2H, s, CH2), 7.02 (lH, dd, J 7.6, 4.7Hz, 5-H), 7.16 ~lH, d, J 7.9Hz, ArH), 7.29-7.43 (6H, m, ArH), 7.59 (2H, dd, J 6.8, 1.4Hz, ArH), 8.05 (lH, d, J 7.9Hz, 4-H), 8.20 (lH, dd, J 4.7, 1.4Hz, 6-H), and 11.49 (lH, br s, NH); rn/z (CI~, NH3) 340 (M+1)+.

F~X~l~IPT,F~ 29 7-~enzvlo~y-2-( lH-pyrrolor2.3-blDvridin-3-ylmethYl )-1.~.3.4-tetr~vtlroisoauinoline ~teD 1: 7-Benzyloxviso~inoline To a solution of 7-hyLoxyisoqllinoline (prepared by the method of R.B. Woodward and W.D. Doering, J. Am. Chem. Soc., 1945, 67, 860) (1.45g, lOmmol) in DMF (20ml) was added sodium hydride (60% dispersion in oil, 0.4g, lOmmol) portionwise. After stirring for 30 minutes, benzyl bromide (1.2ml, 10mmol) was added and the reaction mixture stirred for 2h. The reaction mixture was poured into water and extracted with diethyl ether (3 x lOOml). The ether extracts were combined, washed with 2N
sodium hydroxide solution (2 x 50ml), brine (50ml), dried over m~Fne.~ium sulphate, filtered and evaporated under reduced pressure to give the title compound (1.6g, 68%); ~H (CDCl~) 5.21 (2H, s, OCH2), 7.30-7.51 (7H, m, ArH), 7.59 (lH, d, J 8.3Hz, ArH), 7.75 (lH, d, J 13Hz, ArH), 8.42 (lH, d, J 8Hz, ArH), and 9.14 (lH, s, ArH).

WO 94/20459 ~ PCT/GB94/00384 ~0 Step 2: 7-Benzyloxy-1.2~3.4-tetrahydroisoQuinoline 7-Benzyloxyisoqt~inoline (1.5g, 6.37mmol) in methanol (lOOml) was hydrogenated at 50 psi on a Parr apparatus using 5 platinum oxide (lOOmg) as catalyst. The catalyst was collected by filtration, the filtrate evaporated under reduced pressure to give an oil which crystallised on treatment with hexane/diethyl ether to give the title compound (0.96g, 64%); ~H (CDCl3) 2.72 (2H, t, J 6Hz, CH2), 3.11 (2H, t, J 6Hz, CH2), 3.90 (2H, s, CH2), 6.62 (lH, d, J 2.25Hz, tetrahydroisoquinolinyl H), 6.78 (lH, dd, J
5.75, 2.75Hz, tetrahydroisoquinolinyl H), 6.99 (lH, d, J 9.25Hz, tetrahydroisoquinolinyl H), and 7.25-7.43 (5H, m, ArH).

~teo 3: 7-Renzyloxv-2-(lH-~yrrolor~3-blpvr~din-3 ylmethvl)-1.2.3.4-tetr~ roi~o~llinoline A mixture of 7-benzyloxy-1,2,3,4-tetrahydroisoquinoline (0.48g, ~.mmol) and 3-dimethyl~minomethyl-lH-pyrrolo[2,3-b]pyridine (0.35g, ~mmol) in toluene (5ml) was heated at reflux under nitrogen for 18h. The mixture was allowed to cool and the crystallised product collected. The product was purified by flash chromatography using dichloromethane/methanol (10:1) as eluant. The a~ro~.iate fractions were combined and evaporated to give a solid. Recrystallisation from toluene afforded the tit~e compound (0.24g, 32%) m.p. 180-182C;
(Found: C, 77.73; H, 6.00; N, 11.11. C24H23N30 requires C, 78.02;
H, 6.27; N, 11.37%); ~H (DMSO-d6) 2.68 (4H, m, 2 x CH2), 3.51 (2H, s, CH2), 3.78 (2H, s, CH2),5.01 (2H, s, OCH2), 6.66 (lH, d, J
2.4Hz, ArH), 6.74 (lH, dd, J 8.3, 2.6Hz, ArH), 7.02 (2H, m, ArH), 7.32-7.42 (6H, m, ArH), 8.03 (lH, dd, J 7.9, 1.2Hz, 4-H), 8.18 2~

(lH, dd, J 4.7, 1.5 H z, 6-H ), and 11.47 (lH, br s, NH); m/z (CI~, NH3) 370 (M+1)+.

~AMPT.F, 30 7-(lH-Pyrrolor~.3-blDYri~in-3-vlmethyl)-7-thiophen-3-yl-1 ~.3.4-tet.r~ roi~oallinoline ~tep 1: 7-(3-Thienyl)iso~uinoline Using the method described in ~ mple 28, Step 1 and 3-thiophene boronic acid (lg, 8mmol) the title compo~nd was obtained (0-7g, 54%); OH (CDCl3) 7.47 (lH, dd, J 5.1, 2.9Hz, thiophene 5-H), 7.53 (lH, dd, J 5.1, 1.3Hz, thiophene 4-H), 7.61 (lH, dd, J 2.9, 1.3Hz, thiophene 2-H), 7.64 (lH, d, J 5.7Hz, isoqtlinolinyl H), 7.85 (lH, d, J 8.5Hz, isoquinolinyl H), 7.96 (lH, m, isoquinolinyl H), 8.14 (lH, s, isoquinolinyl H), 8.52 (lH, d, J
5.7Hz, isoquinolinyl 3-H), and 9.28 (lH, s, isoquinolinyl 1-H);
m/z (CI~ ) 212 (M+1)~.
~ tep 2: 2-(lH-Pyrrolor2.3-bl~vridin-3-vlmethyl)-7-thiophen-3-yl-1.2.3.4-tetrahYdroiso~uinoline A solution of 7-(3-thienyl)isoquinoline 10.16g, 3mmol) in 25 dichloromethane was treated with an excess of HCl ~as. The mixture was evaporated under reduced pressure to give a colourless solid. The solid was dissolved in ethanol, platinum oxide (lOOmg) added, the reaction mixture hydrogenated at 50 psi on a Parr apparatus until uptake of hydrogen ceased. The 30 catalyst was collected by filtration and the filtrate was hydrogenated again using fresh catalyst until the starting wo 94no459 ~ PCTIGB94/00384 material had been consumed. The filtrate was evaporated under reduced pressure. The residue was dissolved in ethyl acetate (lOOml), washed with sodium carbonate solution (lOOml), dried over m~Ene~ium sulphate, filtered and evaporated under reduced pressure to give crude 7-(3-thienyl)-1,2,3,4-tetrahydroisoqllinoline as an oil (0.41g, 62%). A mixture of this oil (0.40g, 1.85mmol) and 3-dimethylaminomethyl-lH-pyrrolo[2,3-b]pyridine (0.325g, 1.85mrnol) in toluene (3ml) was heated at reflux under nitrogen for 6h. The mixture was allowed to cool and the crystallised product collected. Recrystallisation from toluene af~orded the tit~e compound (0.17g, 28%), m.p. 228-230C; (Found: C, 72.82; H, 5.46; N, 12.05. C2lHlgN3S requires C, 73.01; H, 6.54; N, 12.16%); ~H (DMSO-d6) 2.72 (2H, t, J 5.4Hz, CH2), 2.80 (2H, t, J 5Hz, CH2), 3.59 (2H, s, CH2), 3.82 (2H, s, CH2), 7.02 (lH, dd, J 7.7, 4.7Hz, 5-H), 7.11 (lH, d, J 8.0Hz, ArH), 7.35 (lH, s, ArH), 7.42-7.50 (3H, m, ArH), 7.57 (lH, dd, J 5.1, 3Hz, ArH), 7.76 (lH, s, ArH), 8.04 (lH, dd, J 7.7, lHz, 4-H), 8.20 (lH, dd, J 4.6, lHz, 6-H), and 11.49 (lH, br s, NH); m/z (CI~, NH3) 345 (M+1)~.
F.~l\IPT F~ 31 6-(4-Chloro~henyl)-2-(lH-~yrrolor2.3-blpyridin-3-ylmethvl )- 1.2.3.4-tetrahvdroisoauinoline Step 1: 6-Hvdroxy-3.4-dihydro-lH-iso~uinoline-2-carboxvlic acid tert-butyl ester To a slurry of 6-hydroxy-1,2,3,4-tetrahydroisoquinoline hydrobromide (prepared by the method of Grimewald, J. Med.
Chem., 1987,30, 2208) (1.2g, 5.2mmol) and triethylamine (0.8ml, WO 94/20459 PCTtGB94/00384 '2 ~ 3 ~

5.7m_ol) in dichloromethane (40ml) was added a solution of di-tert-butyl dicarbonate (1.2g, 5.5mmol) in dichloromethane (lOml). The _ixture was stirred for 2h. The reaction mixture was washed with a solution of citric acid (2 x 50ml), brine (2 x 5 50ml), dried over m~npsium sulphate, filtered and evaporated under reduced pres6ure to give the title compound as an oil (1.3g, 100%); OH (CDCl3) 1.44 (9H, s, C(CH3)3), 2.77 (2H, t, J 6Hz, CH2), 3.79 (2H, br s, CH2), 4.54 (2H, s, CH2), 6.64 (lH, s, ArH), 6.69 (lH, d, J 7.5Hz, ArH), and 6.96 (lH, d, J 8.5Hz, ArH).
~ Ste~ 2: 6-Trift~loroIneth~nesulfonvloxv-3.4--lihvdro-lH-iso~linoline-2-~rboxylic ~-1 tert-butvl ester To a solution of 6-hydroxy-3,4-dihydro-lH-isoquinoline-2-15 carboxylic acid tert-butyl ester (1.3g, 5.2~) and duso~lo~yethyl~mine (lml) in methanol (40ml) at 0C was added a solution of N-phenyltrifluoromethaneslllfo~imide (2.14g, 6mmol). On completion of the addition the reaction mixture was allowed to warm to room temperature and stirred overnight. A
20 further equivalent of diisopropylethyl~mine (lml) was added, the reaction mixture cooled to 0C then a solution of N-phenyltrifluoromet~nesulfonimide (2.14g, 6mmol) was added and the reaction mixture stirred at room temperature for a further 18h. The solvent was evaporated under reduced 25 pressure and the residue purified by flash chromatography using hexane/ethyl acetate (4:1) as eluant. The title compound was obtained as an oil, which was taken on crude to the next step without further purification.

~tep 3: 6-(4-Chlorophenvl)-3~4-dihvdro-lH-isoQuinoline-2-carboxvlic acid tert-butvl ester 2ls6~l~

To a mixture of 6-trifluoromethanesulfonyloxy-3,4-dihydro-lH-isoquinoline-2-carboxylic acid tert-butyl ester (2g, 5.25mmol) and 4-chlorophenyl boronic acid (1.17g, 7.5mmol) in toluene (20ml) was added a 2M sodium carbonate solution (7.5ml). The reaction mixture was stirred under a nitrogen atmosphere, then tetrakis(triphenylphosphine)p~ um(o) (0.29g, 0.~5mmol) was added and the reaction mixture was heated at 90C for 18h. After allowing to cool the reaction mixture was diluted with water (lOOml) and extracted with ethyl acetate (3 x lOOml). The ethyl acetate extracts were combined, dried over magnesium sulphate, filtered and evaporated under reduced pressure to give an oil. Purification by flash chromatography using heY~nP/ethyl acetate as eluant gave the title compound as an oil (0.7g, 39%); ~H (CDCl3) 1.5 (9H, s, C(CH3)3), 2.89 (2H, t, J 8.3Hz, CH2), 3.68 (2H, t, J 8.3Hz, CH2), 4.61 (2H, s, CH2), and 7.15-7.5 (7H, m, ArH).

~tep 4: 6-(4-Chlorophenyl)-1.2.3.4-tetr~llydroiso~inoline To a solution of 6-(4-chlorophenyl)-3,4-dihydro-lH-isoquinoline-2-carboxylic acid tert-butyl ester (0.5g, 1.45mmol) in dichloromethane (6ml) was added trifluoroacetic acid (3ml). The reaction rnilrtl~re was stirred at room temperature for lh. The solvent was evaporated under reduced pressure and the residue partitioned between dichloromethane (3 x 20ml) and lN sodium hydroxide solution (30ml). The combined organic phases were dried over potassium carbonate, filtered and evaporated under reduced pressure to give an oil. The oil was purified by flash chromatography using dichloromethane/methanoVammonia 95:5:1 as eluant to afford the title compound as a solid (0.27g, 2~ 5~

76%); i5H (CDCl3) 2.9 (2H, t, CH2),3.24 (2H, t, CH2), 4.1 (2H, s, CH2), and 7.04-7.55 (7H, m, ArH).

~te~ 5: 6-(4-ChloroDh~rlyl)-2-(lH-pyrrolor2.3-bl~ in-3-ylmeth~ 3~4-tetr~hv~lroiso~llinoline A mixture of 6-(4-chlorophenyl~1,2,3,4-tetrahydroisoquinoline (0.23g,0.94mmol) and 3-dimethyl~minomethyl-lH-pyrrolo[2,3-b]pyridine (0.168g, 0.96mmol) in toluene (15ml) was heated at reflux under nitrogen for 18h. The mixture was allowed to cool and the crystallised product collected. Trituration with ethanol gave the title compound (0.18g, 48%), m.p. 202-204C; (Found: C, 73.02; H, 5.20; N, 11.04. C23H20ClN3Ø2H20 requires C, 73.18; H, 5.45; N, 11.18%); ~iH (CDCl~) 2.83 (2H, t, J 5.5Hz, CH2), 2.94 (2H, t, J
5.5Hz, CH2), 3.73 (2H, s, CH2),3.91 (2H, s, CH2), 7.04-7.10 (2H, m, ArH), 7.29-7.50 (7H, m, ArH),8.12 (7H, dd, J 7.8, 1.5Hz, 4-H), 8.32 (lH, dd, J 4.75, 1.5Hz, 6-H), and 9.60 (lH, br s, NH); m/z (CI~, NH3) 374 (M+1)~.
F~X~l~PT.~, 32 5-Phenyl-2-(lH-pyrrolor2.3-blpyridin-3-ylmethYl)-1.2~3~4-tetrahydroisoQuinoline Using the procedure described for Example 26 repl~cin~ 6-phenyl-1,2,3,4-tetrahydroisoquinoline with 5-phenyl-1,2,3,4-tetrahydroisoquinoline (prepared by the method of L.N. Pridgen, J. Heterocyclic Chem., 1980, 17, 1289) the title compound was obtained as a colourless solid, m.p. 202-204C (toluene); (Found:
C, 81.05; H, 6.31; N, 11.90. C23H2lN3Ø1C7H8Ø1H2O requires C, WO 94/20459 ~ PCT/GB94/00384 81.23; H, 6.33; N, 11.99%); ~H (DMSO-d6) 2.69 (4H, br s, NCH2CH2Ar), 3.45 (2H, s, ArCH2N), 3.78 (2H, s, ArCH2N), 5.08 (2H, s, ArCH2O), 6.60 (lH, d, J 8Hz, 6'-H), 6.81 (lH, d, J 8Hz, 8'-H), 6.95-7.05 (2H, m, ArH), 7.3-7.5 (6H, m, ArH), 8.02 (lH, d, J
8Hz, 4-H), 8.20 (lH, br s, 6-H), and 11.5 (lH, br s, NH); m/z (CI+, NH3) 340 (M+l)~.

EXAMPT F~ 33 5-~enzvloxv-2-(lH-pYrrolor2.3-bl~yridin-3-vlmet4,yl)-1.2.3.4-tetrahydroiso~uinoline Follou~ng the procedure for the preparation of F.lr~mrle 29, repl~n~ 7-hydroxyisoqllinoline in Step 1 with commercially av~ hle 5-hydroxyisoqllin~line, af~orded the title compound as a colourless solid, m.p. 179-181C (MeOH/EtOH); (Found: C, 77.54; H, 6.19; N, 11.09. C24H23N3OØ1H2O requires C, 77.54; H, 6.19; N, 11.09~ H (DMSO-d6) 2.69 (4H, br 8, NCH2CH2Ar), 3.45 (2H, s, ArCH2N), 3.78 (2H, s, ArCH2N), 5.08 (2H, s, ArCH2O), 6.60 (lH, d, J 8Hz, 6'-H), 6.81 (lH, d, J 8Hz, 8'-H), 6.95-7.05 (2H, m, ArH), 7.3-7.5 (6H, m, ArH), 8.02 (lH, d, J 8Hz, 4-H), 8.20 (lH, br s, 6-H), and 11.5 (lH, br s, NH); m/z (CI+, NH3) 370 (M+l)~.

~X~ MpT .~ 34 5-PhenoxY-2-(lH-Dyrrolor2.3-blpyridin-3-YImethyl)-1.2.3.4-tetrahydroisoQuinoline Step 1: 5-Phenoxyiso~uinoline t ~

Cupric oxide (0.2g) was added in one portion to a mixture of phenol (2g, 21mmol), potassium carbonate (2.7g, 20mmol), and 5-bromoisoquinoline (2.1g, 10mmol) in pyridine (20ml) heated at 90C under nitrogen. The mixture was then he7~ted at 140C for 5 18h. After this time the pyridine was removed in vacuo, the residue suspended in ether and the mixture filtered through a pad of silica gel. The solvent was evaporated and the residue purified by column chromatography on silica with ethyl acetate/h~ ne (1:3-1:1) as eluant to give the title compound as a colourless solid (1.lg,49%); OH (CDCl3) 7.1-7.5 (7H, m, ArH), 7.75 (lH,d,J8Hz,ArH),8.02(1H,d,J8Hz,ArH),8.57(1H,d,J8Hz, ArH), and 9.3 (lH, s, 1-H).

~tep 2: 5-Phenoxv-1.~.3.4-tetr~vdroisoQuinoline A solution of 5-pheno~yisoq~linoline (lg,4.5n~nol) in m~t-l~nol (50ml) was ~h~kPn on a Parr hydrogenator at 55 psi hydrogen in the presence of platinum oxide (0.2g) for 3h. The catalyst was then removed by filtration and the solvent evaporated. The residue was triturated with hexane to give the title compound as a colourless solid (0.6g, 60%); OH (CDCl3) 2.65-2.75 (2H, m, ArC~2CH2N), 3.1-3.2 (2H, m, ArCH2CH2N), 4.05 (2H, br s, ArCE2N), 6.75 (lH, d, J 8Hz, ArH), 6.83 (lH, d, J 8Hz, ArH), and 6.9-7.35 (6H, m, ArH); m/z (CI+, NH3) 226 (M+1)+.
~tep 3: 5-Phenoxv-2-(lH-pyrrolor2.3-blpyridin-3-ylmethyl)-1.2.3.4-tetrahYdroiso~uinoline Following the procedure described for F~r~mple 26 replacing 6-phenyl-1,2,3,4-tetrahydroisoquinoline with 5-phenoxy-1,2,3,4-tetrahydroisoquinoline the title compound was WO 94/20459 ~? PCTIGB94/00384 ~s6~

obtained as a colourles6 ~olid, m.p. 179-180C (EtOH/MeOH);
(Found: C, 77.55; H, 5.96; N, 11.68. C23H20N3O requires C,77.94;
H, 5.69; N, 11.86%); OH (CDCl3) 2.8 (4H, m, ArCH2CH2N), 3.71 (2H, s, ArCH2N), 3.89 (2H, s, ArCH2N), 6.72 (lH, d, J 8Hz, ArH), 6.83 (lH, d, J 8Hz, ArH), 6.9-7.35 (8H, m, ArH),8.1 (lH, dd, J 8, 1.5Hz, 4-H), 8.3 (lH, dd, J 4.5, 1.5 H z, 6-H), and 10.1 (lH, br s, NH).

Claims

CLAIMS:

1. A compound of formula I, or a salt or prodrug thereof:

( I ) wherein R represents hydrogen or C1-6 alkyl;
Q represents a moiety of formula Qa, Qb or Qc:

(Qa) (Qb) (Qc) in which the broken line represents an optional chemical bond;
R1 represents hydrogen, or an optionally substituted C1-6 alkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, aryl, aryl(C1-6)alkyl, aryl(C1-6)alkoxy, aryl(C2-6)alkenyl, aryl(C2-6)alkynyl, C3-7 heterocycloalkyl(C1-6)alkyl, heteroaryl, heteroaryl(C1-6)alkyl, heteroaryl(C2-6)alkenyl or heteroaryl(C2-6)alkynyl group;

R2 represents an optionally substituted C1-6 alkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, aryl, aryl(C1-6)alkyl, aryloxy(C1-6)alkyl, aryl(C1-6)alkoxy, aryl(C2-6)alkenyl, aryl(C2-6)alkynyl, C3-7 heterocycloalkyl(C1-6)alkyl, heteroaryl, heteroaryl(C1-6)alkyl, heteroaryl(C2-6)alkenyl or heteroaryl(C2-6)alkynyl group;
R3, R4 and R5 independently represent hydrogen, hydrocarbon, a heterocyclic group, halogen, cyano, trifluoromethyl, nitro, -ORa, -SRa, -SORa, -SO2Ra, -SO2NRaRb, -NRaRb, -NRaCORb, -NRaCO2Rb, -CORa, -CO2Ra or -CONRaRb;
Z represents -CH2- or -CH2CH2-;
R6 represents hydrogen or halogen, or an optionally substituted C1-6 alkyl, C1-6 alkoxy, aryl, aryloxy, aryl(C1-6)alkyl, aryl(C1-6)alkoxy or heteroaryl group; and Ra and Rb independently represent hydrogen, hydrocarbon or a heterocyclic group.

2. A compound as claimed in claim 1 represented by formula IIA, and salts and prodrugs thereof:

(IIA) wherein E represents -(CH2)n-, -CH=CH- or -CC-;
n is zero, 1, 2 or 3;

-X-Y- represents -CH2-CH- or -CH=C-;
W represents a group of formula (i), (ii), (iii), (iv), (v) or (vi):

(I) (II) (III) (IV) (V) (VI) in which V represents oxygen, sulphur or NH: and R13 and R17 independently represent hydrogen, halogen, cyano, nitro, trifluoromethyl, amino, C1-6 alkylamino, di(C1-6)alkylamino, C1-6 alkyl, C1-6 alkoxy, aryl(C1-6)alkoxy or C2-6 alkylcarbonyl.

3. A compound as claimed in claim 2 represented by formula IIB, and salts and prodrugs thereof:

(IIB) wherein n, X, Y, R13 and R17 are as defined in claim 2.

4. A compound as claimed in claim 1 represented by formula IIC, and salts and prodrugs thereof:

(IIC) wherein U represents -CH=CH-, -CC- or -CH2O-; and X, Y, R13 and R17 are as defined in claim 2.

5. A compound as claimed in claim 4 wherein U
represents -CH=CH-.

6. A compound as claimed in claim 1 represented by formula IID, and salts and prodrugs thereof:

(IID) wherein R13 is as defined in claim 2; and R16 represents hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, aryl, halo-aryl, aryloxy, aryl(C1-6)alkyl, aryl(C1-6)alkoxy or heteroaryl.

7. A compound as claimed in claim 1 selected from:
3-(1,2,3,4-tetrahydroisoquinolin-2-yl)methyl-1H-pyrrolo[2,3-b]pyridine;
3-[4-(2-phenylethyl)piperidin-1-yl]methyl-1H-pyrrolo[2,3-b]pyridine;
3-(4-phenyl-1,2,3,6-tetrahydropyrid-1-yl)methyl-1H-pyrrolo[2,3-b]pyridine;
(E)-3-[4-(2-phenylethenyl)-1,2,3,6-tetrahydropyrid-1-yl]methyl-1H-pyrrolo[2,3-b]pyridine;
3-[4-(2-phenylethyl)-1,2,3,6-tetrahydropyrid-1-yl]methyl-1H-pyrrolo[2,3-b]pyridine;
3-[4-(naphth-2-yl)-1,2,3,6-tetrahydropyridin-1-yl]methyl-1H-pyrrolo[2,3-b]pyridine;
3-[4-(4-methoxyphenyl)-1,2,3,6-tetrahydropyridin-1-yl]methyl-1H-pyrrolo[2,3-b]pyridine;
3-[4-(1H-indol-5-yl)-1,2,3,6-tetrahydropyridin-1-yl]methyl-1H-pyrrolo[2,3-b]pyridine:
3-[4-(benzofuran-5-yl)-1,2,3,6-tetrahydropyridin-1-yl]methyl-1H-pyrrolo[2,3-b]pyridine;
3-[4-(benzofuran-6-yl)-1,2,3,6-tetrahydropyridin-1-yl]methyl-1H-pyrrolo[2,3-b]pyridine:
3-[4-(benzothiophen-2-yl)-1,2,3,6-tetrahydropyridin-1-yl]methyl-1H-pyrrolo[2,3-b]pyridine;
3-[4-(benzofuran-2-yl)-1,2,3,6-tetrahydropyridin-1-yl]methyl-1H-pyrrolo[2,3-b]pyridine;
3-[4-(2-phenylethynyl)-1,2,3,6-tetrahydropyridin-1-yl]methyl-1H-pyrrolo[2,3-b]pyridine;
(E)-3-[4-(2-(thiophen-3-yl)ethenyl)-1,2,3,6-tetrahydropyridin-l-yl]methyl-1H-pyrrolo[2,3-b]pyridine;

(E)-3-[4-(2-(2-chlorophenyl)ethenyl)-1,2,3,6-tetrahydropyridin-1-yl]methyl-1H-pyrrolo[2,3-b]pyridine;
(E)-3-[4-(2-(4-chlorophenyl)ethenyl)-1,2,3,6-tetrahydropyridin-1-yl]methyl-1H-pyrrolo[2,3-b]pyridine;
(E)-3-[4-(2-(thiophen-2-yl)ethenyl)-1,2,3,6-tetrahydropyridin-1-yl]methyl-1H-pyrrolo[2,3-b]pyridine;
3-[4-(2-(furan-2-yl)ethyl)-1,2,3,6-tetrahydropyridin-1-yl]methyl-1H-pyrrolo[2,3-b]pyridine;
3-[4-(2-(tetrahydrofuran-2-yl)ethyl)-1,2,3,6-tetrahydropyridin-1-yl]methyl-1H-pyrrolo[2,3-b]pyridine;
3-[4-(2-(5-methylfuran-2-yl)ethyl)-1,2,3,6-tetrahydropyridin-1-yl]methyl-1H-pyrrolo[2,3-b]pyridine;
3-(4-ethyl-1,2,3,6-tetrahydropyridin-1-yl)methyl-1H-pyrrolo[2,3-b]pyridine;
3-(4-benzoyloxymethyl-1,2,3,6-tetrahydropyridin-1-yl)methyl-1H-pyrrolo[2,3-b]pyridine;
(E)-3-[4-(2-(3-methoxyphenyl)ethenyl)-1,2,3,6-tetrahydropyridin-l-yl]methyl-1H-pyrrolo[2,3-b]pyridine;
3-(4-phenoxymethyl-1,2,3,6-tetrahydropyridin-1-yl)methyl-1H-pyrrolo[2,3-b]pyridine;
(E)-3-[4-(2-(5-methylfuran-2-yl)ethenyl)-1,2,3,6-tetrahydropyridin-l-yl]methyl-1H-pyrrolo[2,3-b]pyridine;
3-(6-phenyl-1,2,3,4-tetrahydroisoquinolin-2-yl)methyl-1H-pyrrolo[2,3-b]pyridine;
3-(6-methoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)methyl-1H-pyrrolo[2,3-b]pyridine;
3-(7-phenyl-1,2,3,4-tetrahydroisoquinolin-2-yl)methyl-1H-pyrrolo[2,3-b]pyridine;
3-(7-benzyloxy-1,2,3,4-tetrahydroisoquinolin-2-yl)methyl-1H-pyrrolo[2,3-b]pyridine;
3-[7-(thiophen-3-yl)-1,2,3,4-tetrahydroisoquinolin-2-yl]methyl-1H-pyrrolo[2,3-b]pyridine;
3-[6-(4-chlorophenyl)-1,2,3,4-tetrahydroisoquinolin-2-yl]methyl-1H-pyrrolo[2,3-b]pyridine;
3-(5-phenyl-1,2,3,4-tetrahydroisoquinolin-2-yl)methyl-1H-pyrrolo[2,3-b]pyridine;

3-(5-benzyloxy-1,2,3,4-tetrahydroisoquinolin-2-yl)methyl-1H-pyrrolo[2,3-b]pyridine;
3-(5-phenoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)methyl-1H-pyrrolo[2,3-b]pyridine;
and salts and prodrugs thereof.

8. A pharmaceutical composition comprising a compound as claimed in any one of the preceding claims in association with a pharmaceutically acceptable carrier.

9. A compound as claimed in any one of claims 1 to 7 for use in therapy.

10. The use of a compound as claimed in any one of claims 1 to 7 for the manufacture of a medicament for the treatment and/or prevention of disorders of the dopamine system.

11. A process for the preparation of a compound as claimed in claim 1 which comprises:

(A) reacting a compound of formula III with a compound of formula IV:

(III) (IV) wherein R3, R4 and R5 are as defined in claim 1, Q1 represents the residue of a moiety of formula Qa to Qc as defined in claim 1, and RP corresponds to the group R as defined in claim 1 or represents a suitable protecting group; in the presence of a substantially equimolar amount of formaldehyde; followed, where required, by removal of the protecting group RP; and subsequently, if necessary, N-alkylation by standard methods to introduce the moiety R; or (B) reacting a compound of formula IV as defined above with a compound of formula V:

(V) wherein R3, R4 and R5 are as defined in claim 1, RP is as defined above, and L represents a suitable leaving group;
followed, where required, by removal of the protecting group RP; and subsequently, if necessary, N-alkylation by standard methods to introduce the moiety R; and (C) subsequently, where required, converting a compound of formula I initially obtained into a further compound of formula I by conventional methods.

12. A method for the treatment and/or prevention of disorders of the dopamine system, which method comprises administering to a patient in need of such treatment an effective amount of a compound as claimed in any one of claims 1 to 7.